Navidea Biopharmaceuticals (NAVB) 8-K 15 Dec 17 2016 FY Other Events Financial data

Document And Entity Information

Document And Entity Information - shares	12 Months Ended
	Dec. 31, 2016	Mar. 01, 2017
Document Information [Line Items]
Entity Registrant Name	NAVIDEA BIOPHARMACEUTICALS, INC.
Entity Central Index Key	810,509
Trading Symbol	navb
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		161,898,338
Document Type	8-K
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash	$ 1,539,325	$ 7,166,260
Restricted cash	5,001,253
Accounts and other receivables	203,016	10,439
Inventory, net	96,208
Prepaid expenses and other	842,220	882,237
Assets associated with discontinued operations, current	3,144,247	4,518,238
Total current assets	10,826,269	12,577,174
Property and equipment	3,232,372	3,518,779
Less accumulated depreciation and amortization	2,051,787	1,742,583
Property and equipment, net	1,180,585	1,776,196
Patents and trademarks	146,685	178,087
Less accumulated amortization		31,402
Patents and trademarks, net	146,685	146,685
Other assets	202,882	273,573
Assets associated with discontinued operations, non-current	105,255	190,885
Total assets	12,461,676	14,964,513
Current liabilities:
Accounts payable	5,165,385	1,525,303
Accrued liabilities and other	7,857,856	2,179,348
Deferred revenue, current	15,037	1,044,281
Notes payable, current	51,957,913	333,333
Liabilities associated with discontinued operations, current	4,865,597	1,101,585
Total current liabilities	69,861,788	6,183,850
Deferred revenue	26,061	192,728
Notes payable, net of current portion and discounts of $0 and $2,033,506, respectively	9,641,179	60,746,002
Other liabilities	598,861	677,633
Liabilities associated with discontinued operations, non-current		1,000,000
Total liabilities	80,127,889	68,800,213
Commitments and contingencies (Note 14)
Stockholders’ deficit:
Preferred stock; $.001 par value; 5,000,000 shares authorized; no shares issued or outstanding at December 31, 2016 and 2015, respectively
Common stock; $.001 par value; 300,000,000 shares authorized; 155,762,729 and 155,649,665 shares issued and outstanding at December 31, 2016 and 2015, respectively	155,763	155,650
Additional paid-in capital	326,564,148	326,085,743
Accumulated deficit	(394,855,034)	(380,546,651)
Total Navidea stockholders' deficit	(68,135,123)	(54,305,258)
Non-controlling interest	468,910	469,558
Total stockholders’ deficit	(67,666,213)	(53,835,700)
Total liabilities and stockholders’ deficit	$ 12,461,676	$ 14,964,513

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Notes payable, discounts	$ 0	$ 2,033,506
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares issued (in shares)	155,762,729	155,649,665
Common stock, shares outstanding (in shares)	155,762,729	155,649,665

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
Revenue:
Tc99m tilmanocept sales revenue	$ 39,601		$ 19,075		$ 13,200
Tc99m tilmanocept license revenue	1,795,625		1,133,333		300,000
Grant and other revenue	3,136,408		1,860,953		1,740,896
Total revenue	4,971,634		3,013,361		2,054,096
Cost of goods sold	62,260		3,226		2,626
Gross profit	4,909,374		3,010,135		2,051,470
Operating expenses:
Research and development	7,138,080		10,562,729		15,116,978
Selling, general and administrative	7,920,036		10,888,146		9,525,984
Total operating expenses	15,058,116		21,450,875		24,642,962
Loss from operations	(10,148,742)	[1]	(18,440,740)	[1]	(22,591,492)
Other income (expense):
Interest expense, net	(4,866)		(1,269,916)		(3,363,731)
Equity in loss of R-NAV, LLC	(15,159)		(305,253)		(523,809)
Loss on disposal of investment in R-NAV, LLC	(39,732)
Change in fair value of financial instruments	2,858,524		(614,782)		(1,342,389)
Loss on extinguishment of debt			(2,440,714)		(2,610,196)
Other, net	(27,919)		26,808		72,749
Total other income (expense), net	2,770,848		(4,603,857)		(7,767,376)
Loss from continuing operations	(7,377,894)		(23,044,597)		(30,358,868)
Loss from discontinued operations, net of tax effect	(6,931,137)		(4,518,938)	[2]	(5,367,801)
Net loss	(14,309,031)		(27,563,535)		(35,726,669)
Less loss attributable to noncontrolling interest	(648)		(855)
Deemed dividend on beneficial conversion feature of MT Preferred Stock			(46,000)
Net loss attributable to common stockholders	$ (14,308,383)		$ (27,608,680)		$ (35,726,669)
Loss per common share (basic and diluted):
Continuing operations (in dollars per share)	$ (0.05)		$ (0.15)		$ (0.20)
Discontinued operations (in dollars per share)	(0.04)		(0.03)		(0.04)
Attributable to common stockholders (in dollars per share)	$ (0.09)		$ (0.18)		$ (0.24)
Weighted average shares outstanding (basic and diluted) (in shares)	155,422,384		151,180,222		148,748,396
[1]	Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments.
[2]	Amount not allocated to a reportable segment represents contingent consideration recognized related to 2015 GDS Business revenue royalties pursuant to the 2011 sale of the GDS Business to Devicor, net of tax effect. See Note 1(a).

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2013	7,565	135,919,423
Balance at Dec. 31, 2013	$ 8	$ 135,919	$ 313,111,788	$ (317,257,302)		$ (4,009,587)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		299,360				468,000
Issued stock upon exercise of stock options, net		$ 300	(51,669)			$ (51,369)
Stock Issued During Period, Shares, Restricted Stock Award, Gross		380,250
Issued restricted stock		$ 380				380
Canceled stock to pay employee tax obligations (in shares)		(6,582)
Canceled stock to pay employee tax obligations		$ (6)	(8,813)			(8,819)
Canceled forfeited restricted stock (in shares)		(300,000)
Canceled forfeited restricted stock		$ (300)				$ (300)
Stock Issued During Period, Shares, Employee Benefit Plan		36,455				36,455
Issued stock to 401(k) plan		$ 36	100,007			$ 100,043
Conversion of Series B Preferred Stock to common stock, net (in shares)	(3,046)	9,960,420
Conversion of Series B Preferred Stock to common stock, net	$ (4)	$ 9,960	(9,956)
Issued warrants in connection with debt issuance			464,991			464,991
Issued stock upon exchange of warrants (in shares)		3,843,223
Issued stock upon exchange of warrants		$ 3,843	7,682,930			7,686,773
Issued stock in payment of Board retainers (in shares)		67,710
Issued stock in payment of Board retainers		$ 68	89,307			89,375
Recovery of shareholder short swing profits			17,554			17,554
Stock compensation expense			1,634,162			1,634,162
Net Income (Loss) Attributable to Parent				(35,726,669)		(35,726,669)
Balance (in shares) at Dec. 31, 2014	4,519	150,200,259
Balance at Dec. 31, 2014	$ 4	$ 150,200	323,030,301	(352,983,971)		$ (29,803,466)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		124,238				146,625
Issued stock upon exercise of stock options, net		$ 124	54,206			$ 54,330
Stock Issued During Period, Shares, Restricted Stock Award, Gross		354,000
Issued restricted stock		$ 354				354
Canceled stock to pay employee tax obligations (in shares)		(7,645)
Canceled stock to pay employee tax obligations		$ (7)	(12,607)			$ (12,614)
Canceled forfeited restricted stock (in shares)		(158,000)
Canceled forfeited restricted stock		$ (158)	158
Stock Issued During Period, Shares, Employee Benefit Plan		68,157				68,157
Issued stock to 401(k) plan		$ 68	117,031			$ 117,099
Issued stock in payment of Board retainers (in shares)		90,977
Issued stock in payment of Board retainers		$ 91	172,878			172,969
Stock compensation expense			2,368,685			2,368,685
Net Income (Loss) Attributable to Parent				(27,562,680)	$ (855)	(27,563,535)
Exchanged Series B Preferred Stock for warrants (in shares)	(4,519)
Exchanged Series B Preferred Stock for warrants	$ (4)		4
Extension of warrant expiration date			149,615			149,615
Issued warrants in connection with advisory services agreement			256,450			256,450
Issued stock upon exercise of warrants (in shares)		4,977,679
Issued stock upon exercise of warrants		$ 4,978	(4,978)
Issuance of MT Preferred Stock, net of deemed dividend			(46,000)		470,413	424,413
Balance (in shares) at Dec. 31, 2015		155,649,665
Balance at Dec. 31, 2015		$ 155,650	326,085,743	(380,546,651)	469,558	$ (53,835,700)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		50,000				50,000
Issued stock upon exercise of stock options, net		$ 50	13,450			$ 13,500
Stock Issued During Period, Shares, Restricted Stock Award, Gross		168,000
Issued restricted stock		$ 168				168
Canceled forfeited restricted stock (in shares)		(256,000)
Canceled forfeited restricted stock		$ (256)	228			$ (28)
Stock Issued During Period, Shares, Employee Benefit Plan		67,002				67,002
Issued stock to 401(k) plan		$ 67	120,733			$ 120,800
Issued stock in payment of Board retainers (in shares)		84,062
Issued stock in payment of Board retainers		$ 84	66,455			66,539
Stock compensation expense			277,539			277,539
Net Income (Loss) Attributable to Parent				(14,308,383)	(648)	(14,309,031)
Balance (in shares) at Dec. 31, 2016		155,762,729
Balance at Dec. 31, 2016		$ 155,763	$ 326,564,148	$ (394,855,034)	$ 468,910	$ (67,666,213)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net loss	$ (14,309,031)	$ (27,563,535)	$ (35,726,669)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization of property and equipment	496,178	562,468	487,906
Amortization of patents and trademarks	5,191	8,951	12,277
Loss on disposal and abandonment of assets	136,719	33,184	31,794
Gain on forgiveness of accounts payable	(85,355)
Change in inventory reserve	43,354	143,493	539,027
Amortization of debt discount and issuance costs	77,964	492,963	844,250
Debt discount and issuance costs written off	1,955,541
Prepayment premium and debt collection fees related to long term debt	2,923,271
Compounded interest on long term debt	1,561,568	2,048,960
Stock compensation expense	277,539	2,368,685	1,634,162
Equity in loss of R-NAV, LLC	15,159	305,253	523,809
Loss on disposal of investment in R-NAV, LLC	39,732
Change in fair value of financial instruments	(2,858,524)	614,782	1,342,389
Loss on extinguishment of debt		2,440,714	2,610,196
Issued stock to 401(k) plan for employer matching contributions	120,800	117,099	100,043
Extension of warrant expiration date		149,615
Issued warrants in connection with advisory services agreement		256,450
Value of restricted stock issued to directors	66,539	172,969	89,375
Other	(15,159)	(63,677)	(38,657)
Changes in operating assets and liabilities:
Accounts and other receivables	1,882,855	(2,808,696)	334,082
Inventory	(861,274)	135,986	761,024
Prepaid expenses and other assets	187,379	263,915	(476,860)
Accounts payable	5,441,155	290,024	(944,850)
Accrued liabilities and other liabilities	5,351,090	(282,642)	(1,250,047)
Deferred revenue	1,104,089	1,237,009
Net cash provided by (used in) operating activities	3,556,780	(19,076,030)	(29,126,749)
Cash flows from investing activities:
Purchases of equipment	(1,847)	(39,001)	(1,114,448)
Proceeds from sales of equipment	45,000	38,265
Patent and trademark costs		(27,092)	(77,184)
Investment in R-NAV, LLC			(333,334)
Payments on disposal of investment in R-NAV, LLC	(110,000)
Proceeds from disposal of investment in R-NAV, LLC	27,623
Net cash used in investing activities	(39,224)	(27,828)	(1,524,966)
Cash flows from financing activities:
Proceeds from issuance of MT Preferred Stock and warrants		500,000
Payment of preferred stock issuance costs		(12,587)
Proceeds from issuance of common stock, net	13,640	65,975	87,984
Payment of tax withholdings related to stock-based compensation	0	(23,906)	(130,537)
Proceeds from notes payable		54,500,000	30,000,000
Payment of debt-related costs	(3,923,271)	(3,902,487)	(1,763,526)
Principal payments on notes payable	(231,453)	(30,333,333)	(25,000,000)
Restricted cash held for payment against debt	(5,001,253)
Payments under capital leases	(2,154)	(2,550)	(2,226)
Net cash (used in) provided by financing activities	(9,144,491)	20,791,112	3,191,695
Net (decrease) increase in cash	(5,626,935)	1,687,254	(27,460,020)
Cash, beginning of period	7,166,260	5,479,006	32,939,026
Cash, end of period	$ 1,539,325	$ 7,166,260	$ 5,479,006

Note 1 - Organization and Summa

Note 1 - Organization and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Significant Accounting Policies [Text Block]	1. Organization and Summary of Significant Accounting Policies a. Organization and Nature of Operations: Navidea ’s Manocept platform is predicated on the ability to specifically target the CD206 ® Tc99m first Tc99m On March 3, 2017, November 23, 2016, ( 414, 414” ’s radioactive diagnostic agent marketed under the Lymphoseek ® Upon closing of the Asset Sale, the Supply and Distribution Agreement, dated November 15, 2007 ( 414 no The Asset Sale to Cardinal Health 414 March 2017 Our consolidated balance sheets and statements of operations have been reclassified, as required, for all periods presented to reflect the Business as a discontinued operation. Cash flows associated with the operation of the Business have been combined with operating, investing and financing cash flows, as appropriate, in our consolidated statements of cash flows. Other than Tc99m none In January 2015, From our inception through August 2011, “GDS Business”). We sold the GDS Business to Devicor Medical Products, Inc. (“Devicor”) in August 2011. $30.3 $20 2017. $759,000, 2015 2015 $1.2 $436,000 2015. not 2015 2016. In December 2001, August 2009, ’s Board of Directors decided to discontinue the operations and attempt to sell Cardiosonix. However, we were obligated to continue to service and support the Cardiosonix devices through 2013. not In July 2011, Tc99m 100% b. Principles of Consolidation: May 2016, not 11. c. Use of Estimates: d. Financial Instruments and Fair Value: 1 3 three Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2 – Quoted prices in markets that are not Level 3 – Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. A financial instrument ’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. In determining the appropriate levels, we perform a detailed analysis of the assets and liabilities whose fair value is measured on a recurring basis. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no 3. 4. The following methods and assumptions were used to estimate the fair value of each class of financial instruments: ( 1 Cash, restricted cash, accounts and other receivables, accounts payable, and accrued liabilities: The carrying amounts approximate fair value because of the short maturity of these instruments. At December 31, 2016, 13. December 31, 2016, $894,000 December 31, 2016. ( 2 Notes payable: The carrying value of our debt at December 31, 201 6 2015 December 31, 2016 2015, 3 December 31, 2016 2015, $153,000 $3.0 4 13. ( 3 Derivative liabilities: Derivative liabilities are related to certain outstanding warrants which are recorded at fair value. Derivative liabilities totaling $63,000 December 31, 2016 2015 December 31, 2016 2015 4. e. Stock-Based Compensation: December 31, 2016, two 2002 “2002 2014 “2014 2014 may may 12 5 2002 no may Stock options granted under the 2002 2014 one four not ten 90 ’s separation from employment with the Company. We issue new shares of our common stock upon exercise of stock options. In September 2016, 2016 “2016 10 2016 not ’s stockholders. In connection with Dr. Goldberg’s appointment as Chief Executive Officer of the Company in September 2016, 5,000,000 2016 100% five $2.50 tenth Stock-based payments to employees and directors, including grants of stock options, are recognized in the consolidated statement of operations based on their estimated fair values. The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. Expected volatilities are based on the Company ’s historical volatility, which management believes represents the most accurate basis for estimating expected future volatility under the current circumstances. Navidea uses historical data to estimate forfeiture rates. The expected term of stock options granted is based on the vesting period and the contractual life of the options. The risk-free rate is based on the U.S. Treasury yield in effect at the time of the grant. The assumptions used to calculate the fair value of stock option awards granted during the years ended December 31, 2016, 2015 2014 2016 2015 2014 Expected volatility 59% - 75% 61% - 64% 61% - 67% Weighted-average volatility 60% 62% 65% Expected dividends — — — Expected term (in years) 5.0 - 6.0 5.1 - 6.3 5.3 - 7.4 Risk-free rate 1.2% - 1.8% 1.5% - 1.9% 1.6% - 2.0% The portion of the fair value of stock-based awards that is ultimately expected to vest is recognized as compensation expense over either ( 1 2 may ’s estimates of the probable dates of the vesting events. Stock-based awards that do not not 5. f. Cash and Cash Equivalents: 3 g. Accounts and Other Receivable s : 7. h. Inventory: first first 8. i. Property and Equipment: 9. j. Intangible Assets: 5 15 no k. Impairment or Disposal of Long-Lived Assets: may not No December 31, 2016, 2015 2014. l. Leases: not 21. m. Derivative Instruments: not one one not n . Revenue Recognition: Prior to the Asset Sale to Cardinal Health 414 March 2017, no may We earned additional revenues based on a percentage of the actual net re venues achieved by Cardinal Health 414 414 414, 414. December 31, 2016 2015, 99% 414. 414 December 31, 2016, 2015 2014 3. We also earn revenues related to our licensing and distribution agreements. The terms of these agreements may not $2.0 March 2015. not not not two $417,000 September 2016, We generate additional revenue from grants to support various product dev elopment initiatives. We generally recognize grant revenue when expenses reimbursable under the grants have been paid and payments under the grants become contractually due. Lastly, we recognized revenues from the provision of services to R-NAV and its subsidiaries through the termination of the R-NAV joint venture on May 31, 2016. 11. o . Research and Development Costs: p. Income Taxes: December 31, 2016 2015. Current accounting standards include guidance on the accounting for uncertainty in income taxes recognized in the financial statements. Such standards also prescribe a recognition threshold and measurement model for the financial statement recognition of a tax position taken, or expected to be taken, and provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company believes that the ultimate deductibility of all tax positions is highly certain, although there is uncertainty about the timing of such deductibility. As a result, no December 31, 201 6 2015 not twelve December 31, 2016, 2013 2016 18. q . Change in Accounting Principle: April 2015, No. 2015 03, Simplifying the Presentation of Debt Issuance Costs 2015 03 not 2015 03. 2015 03 December 15, 2015, 2015 03 2015, 2015 03. December 31, 2016 2015, 2015 03 no In November 2015, No. 2015 17, Balance Sheet Classification of Deferred Taxes 2015 17 2015 17 may 2015 17 December 31, 2015 2015 17 As a result of the Asset Sale, our consolidated balance sheets and statements of operations have been reclassified, for all periods presented to reflect the Business as a discontinued operation, including interest expense related to the CRG and Platinum notes, as required by Accounting Standards Codification 205 20 45 6. r . Recent Accounting Standards: In August 2014, No. 2014 15, Presentation of Financial Statements-Going Concern . ASU 2014 15 2014 15 one 2014 15 December 15, 2016, 2014 15 not In February 2016, No. 2016 02, Leases (Topic 842 . ASU 2016 02 842 2016 02 December 15, 2018, 2016 02 2016 02 In March 2016, ued ASU No. 2016 08, Revenue from Contracts with Customers – Principal versus Agent Considerations (Reporting Revenue Gross versus Net) . ASU 2016 08 not 2016 08 No. 2014 09, Revenue from Contracts with Customers (Topic 606 not 2016 08 2014 09, one No. 2015 14, Revenue from Contracts with Customers – Deferral of the Effective Date . Public business entities should adopt the new revenue recognition standard for annual reporting periods beginning after December 15, 2017, December 15, 2016, 2014 09 may 414 March 2017. In March 2016, No. 2016 09, Compensation – Stock Compensation . ASU 2016 09 2016 09 December 15, 2016, 2016 09 2016 09 In April 2016, No. 2016 10, Revenue from Contracts with Customers – Identifying Performance Obligations and Licensing . ASU 2016 10 not 2016 10 No. 2014 09, Revenue from Contracts with Customers (Topic 606 not 2016 10 2014 09, one No. 2015 14, Revenue from Contracts with Customers – Deferral of the Effective Date . Public business entities should adopt the new revenue recognition standard for annual reporting periods beginning after December 15, 2017, December 15, 2016, 2016 120 may 414 March 2017. In May 2016, No. 2016 12, Revenue from Contracts with Customers – Narrow-Scope Improvements and Practical Expedients . ASU 2016 12 not 606, 2016 12 No. 2014 09, Revenue from Contracts with Customers (Topic 606 not 2016 12 2014 09, one No. 2015 14, Revenue from Contracts with Customers – Deferral of the Effective Date . Public business entities should adopt the new revenue recognition standard for annual reporting periods beginning after December 15, 2017, December 15, 2016, 2016 12 may 414 March 2017. In August 2016, No. 2016 15, Statement of Cash Flows – Classification of Certain Cash Receipts and Cash Payments . ASU 2016 15 2016 15 December 15, 2017, 2016 15 2016 15 2016 15 December 31, 2016. In November 2016, No. 2016 18, Statement of Cash Flows – Restricted Cash . ASU 2016 18 2016 18 December 15, 2017, 2016 18 March 2017, not 2016 18 In December 2016, No. 2016 20, Technical Corrections and Improvements to Topic 606, . ASU 2016 20 not 606, 606, 2016 20 No. 2014 09, Revenue from Contracts with Customers (Topic 606 not 2016 12 2014 09, one No. 2015 14, Revenue from Contracts with Customers – Deferral of the Effective Date . Public business entities should adopt the new revenue recognition standard for annual reporting periods beginning after December 15, 2017, December 15, 2016, 2016 20 may 414 March 2017. In January 2017, No. 2017 01, Business Combinations (Topic 805 . ASU 2017 01 not not not 2017 01 1 2 2017 01 December 15, 2017, 2017 01 No 2017 01. 2017 01

Note 2 - Liquidity

Note 2 - Liquidity	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	2. Liquidity Prior to the Asset Sale to Cardinal Health 414 March 2017, ll of our material assets, except our intellectual property, were pledged as collateral for our borrowings under the Term Loan Agreement (the “CRG Loan Agreement”) with CRG. In addition to the security interest in our assets, the CRG Loan Agreement carried covenants that imposed significant requirements on us, including, among others, requirements that we ( 1 2 $5 3 $22.5 Tc99m 2016 14% 18% During the course of 2016, June 22, 2016, one $4.1 On March 3, 2017, 414 February 22, 2017. March 3, 2017, $59 no no $47 no $66 414 $7 414’s $12 one 414 414 $59 first 414, 414 414 414 414, 414 $2 $3 March 3, 2017, 414 $7 March 7, 2017, $12 13 25 In addition, our Loan Agreement with Platinum (the “Platinum Loan Agreement”) carries standard non-financial covenants typical for commercial loan agreements, many of which are similar to those contained in the CRG Loan Agreement, that impose significant requirements on us. Our ability to comply with these provisions may The Platinum Loan Agreement includes a covenant that results in an event of default on the Platinum Loan Agreement upon default on the CRG Loan Agreement. As discussed above, the Company is maintaining its position that CRG ’s alleged claims do not not In connection with the closing of the Asset Sale to Cardinal Health 414, approximately $7.7 $1.9 not 13 25 Post-closing and after paying off our outstanding indebtedness and transaction-related expenses, Navidea has approximately $15.6 $3.7 4694 414 $7 twelve 10

Note 3 - Discontinued Operation

Note 3 - Discontinued Operations	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	3. Discontinued Operations In August 2011, the GDS Business to Devicor. We recorded net income of $759,000 2015 2015 $1.2 $436,000 On March 3, 2017, to Cardinal Health 414 ® 414 $80.6 $3 As a result of the sale of the GDS Business to Devicor, and the Asset Sale to Cardinal Health 414, December 31, 201 6 December 31, 201 5 Accounts and other receivables $ 1,598,994 $ 3,692,747 Inventory, net 1,374,618 652,906 Prepaid expenses 170,635 172,585 Assets associated with discontinued operations, current 3,144,247 4,518,238 Property and equipment, net of accumulated depreciation 70,973 151,412 Patents and trademarks, net of accumulated amortization 34,282 39,473 Assets associated with discontinued operations, noncurrent 105,255 190,885 Total assets associated with discontinued operations $ 3,249,502 $ 4,709,123 Accounts payable $ 1,957,938 $ 242,220 Accrued liabilities 607,659 859,365 Deferred revenue 2,300,000 — Liabilities associated with discontinued operations, current 4,865,597 1,101,585 Other liabilities — 1,000,000 Total l iabilities associated with discontinued operations $ 4,865,597 $ 2,101,585 In addition, we reported certain revenues related to the sale of the GDS Business to Devicor, as well as certain revenues and expenses related to the Asset Sale to Cardinal Health 414, Years Ended December 31, 2016 2015 2014 Revenue: Lymphoseek sales revenue $ 16,997,497 $ 10,235,277 $ 4,220,753 Royalties on GDS Business — 1,194,660 — Grant and other revenue 575 669 — Total revenue 16,998,072 11,430,606 4,220,753 Cost of goods sold 2,234,780 1,751,537 1,583,519 Gross profit 14,763,292 9,679,069 2,637,234 Operating expenses: Research and development 1,744,496 2,225,004 1,662,611 Selling, general and administrative 5,093,529 6,369,183 6,016,087 Total operating expenses 6,838,025 8,594,187 7,678,698 Income (l oss) from discontinued operations 7,925,267 1,084,882 (5,041,464 ) Interest expense (14,856,404 ) (5,603,820 ) (326,337 ) Loss from discontinued operations $ (6,931,137 ) $ (4,518,938 ) $ (5,367,801 )

Note 4 - Fair Value

Note 4 - Fair Value	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Fair Value Disclosures [Text Block]	4 . Fair Value Platinum ha s the right to convert into common stock all or any portion of the unpaid principal or unpaid interest accrued on all draws under the Platinum credit facility, under certain circumstances. The Platinum embedded option to convert such debt into common stock is recorded at fair value on the consolidated balance sheets and deemed to be a derivative instrument as the amount of shares to be issued upon conversion is indeterminable. The estimated fair value of the conversion option of the Platinum Note is approximately $153,000 $3.0 December 31, 2016 2015, 13. MT issued warrants to purchase MT Common Stock with certain characteristics including a net settlement provision that require the warrants to be accounted for as a derivative liability at fair value on the consolidated balance sheets. The estimated fair value of the MT warrants is $63,000 both December 31, 2016 2015, 1 10. The following tables set forth, by level, financial liabilities measured at fair value on a recurring basis: Liabilities Measured at Fair Value on a Recurring Basis as of December 31, 2016 Quoted Prices in Active Markets for Identical Assets and Liabilities Significant Other Observable Inputs Significant Unobservable Inputs (a)(b) Balance as of December 31, Description (Level 1) (Level 2) (Level 3) 2016 Platinum conversion option $ — $ — $ 153,357 $ 153,357 Liability related to MT warrants — — 63,000 63,000 Liabilities Measured at Fair Value on a Recurring Basis as of December 31, 2015 Quoted Prices in Active Markets for Identical Assets and Liabilities Significant Other Observable Inputs Significant Unobservable Inputs (a)(b) Balance as of December 31, Description (Level 1) (Level 2) (Level 3) 2015 Platinum conversion option $ — $ — $ 3,011,880 $ 3,011,880 Liability related to MT warrants — — 63,000 63,000 a. Valuation Processes-Level 3 third third The assumptions used in the Monte Carlo simulation as of December 31, 2016 2015 2016 2015 Estimated volatility 76 % 58 % Expected term (in years) 4.75 5.75 Debt rate 8.125 % 14.125 % Beginning stock price $ 0.64 $ 1.33 In addition, as of December 31, 2016 95% 414 first 2017. b. Sensitivity Analysis-Level 3 one not There were no 1 or Level 2 December 31, 2016 2015. no 1 2 December 31, 2016 2015. 3 3 December 31, 2016, 2015 2014 $2.9 $615,000 $1.3

Note 5 - Stock-based Compensati

Note 5 - Stock-based Compensation	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	5 . Stock-Based Compensation For the years ended December 31, 201 6, 2015 2014, $224,000, $2.4 $1.6 not December 31, 2016, 2015 2014. A summary of the status of our stock options as of December 31, 2016, Year Ended December 31, 2016 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding at beginning of year 5,437,064 $ 1.96 Granted 479,457 1.05 Exercised (50,000 ) 0.27 Canceled and forfeited (2,186,906 ) 1.69 Expired (299,000 ) 2.42 Outstanding at end of year 3,380,615 $ 2.00 6.5 $ 16,013 Exercisable at end of year 2,548,681 $ 2.07 6.1 $ 16,013 The weighted average grant-date fair value of options granted in 201 6, 2015, 2014 $0.53, $1.67 $1.56, 2016, 50,000 $23,000 50,000 $13,500. 2015, 146,625 $144,000 124,238 $66,000. 2014, 468,000 $582,000 299,360 $70,000. 2016, 2015, 2014, $3,000, $277,000 $4,000, A summary of the status of our unvested restricted stock as of December 31, 2016, Year Ended December 31, 2016 Number of Shares Weighted Average Grant-Date Fair Value Unvested at beginning of year 361,000 $ 1.69 Granted 168,000 1.20 Forfeited (206,000 ) 1.77 Expired (50,000 ) 1.93 Vested (66,000 ) 1.65 Unvested at end of year 207,000 $ 1.17 During 201 6, 2015 2014, 66,000, 333,250 216,250 $63,000, $511,000 $387,000, In February 2016, 100,000 $96,000 2016, 66,000 $63,000 2016, 106,000 $118,000 During 2015, 120,000 $193,000 2015, 193,250 $286,000 2015, 27,000 $50,000 April 2015, 20,000 $32,000 upon reaching a milestone as defined by the terms of the restricted stock agreement. In May 2015, 20,000 $25,000 July 2015, 61,000 $107,000 During 2014, 61,250 $111,000 2014, 4 0,000 $52,000 March 2014, 100,000 $205,000 May 2014, 175,000 $278,000 September 2014, 125,000 $166,000 December 2014, 15,000 $19,000 During 2015 and 2014, $24,000 $131,000, No 2016. December 31, 2016, $223,000 1.2 1

Note 6 - Earnings Per Share

Note 6 - Earnings Per Share	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Earnings Per Share [Text Block]	6 . Earnings Per Share Basic (loss) earnings per share is calculated by dividing net (loss) income attributable to common stockholders by the weighted-average number of common shares and, except for periods with a loss from operations, participating securities outstanding during the period. Diluted (loss) earnings per share reflects additional common shares that would have been outstanding if dilutive potential common shares had been issued. Potential common shares that may The following table sets forth the calculation of basic and diluted (loss) earnings per share for the years ended December 31, 2016, 2015 2014: Years Ended December 31, 2016 2015 2014 Net loss $ (14,309,031 ) $ (27,563,535 ) $ (35,726,669 ) Less loss attributable to noncontrolling interest (648 ) (855 ) — Deemed dividend on beneficial conversion feature of MT Preferred Stock — (46,000 ) — Net loss attributable to common stockholders $ (14,308,383 ) $ (27,608,680 ) $ (35,726,669 ) Loss per common share (basic and diluted): Continuing operations $ (0.05 ) $ (0.15 ) $ (0.20 ) Discontinued operations $ (0.04 ) $ (0.03 ) $ (0.04 ) Attributable to common stockholders $ (0.09 ) $ (0.18 ) $ (0.24 ) Weighted average shares outstanding (basic and diluted) 155,422,384 151,180,222 148,748,396 Diluted (loss) earnings per common share for the years ended December 31, 2016, 2015 2014 14.1 14.6 19.0 The Company ’s unvested stock awards contain nonforfeitable rights to dividends or dividend equivalents, whether paid or unpaid (referred to as “participating securities”). Therefore, the unvested stock awards are required to be included in the number of shares outstanding for both basic and diluted earnings per share calculations. However, due to our loss from continuing operations, 207,000, 361,000 498,250 December 31, 2016, 2015 2014, Certain revenue and expense amounts in the years ended December 31, 2016, 2015 2014 See Note 3.

Note 7 - Accounts and Other Rec

Note 7 - Accounts and Other Receivables and Concentrations of Credit Risk	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	7 . Accounts and Other Receivables and Credit Risk Accounts and other receivables at December 31, 2016 2015 2016 2015 Trade $ 18,420 $ — Other 184,596 10,439 Total $ 203,016 $ 10,439 As of December 31, 2016 2015, no We believe that we have adequately addressed credit risks in estimating the allowance for doubtful accounts. Accounts and other receivables in the amount of $1,598,994 $3,692,747 December 31, 2016 2015, See Note 3.

Note 8 - Inventory

Note 8 - Inventory	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Inventory Disclosure [Text Block]	8 . Inventory The components of net inventory at December 31, 201 6 2015, $0 $14,000, 2016 2015 Materials $ 94,500 $ — Work-in-process 1,708 14,436 Finished goods — — Reserves — (14,436 ) Total $ 96,208 $ — During 2016 2015, $131,000 $446,000, Tc99m 2016 2015, $43,000 $52,000 Tc99m no 2016 2015, $0 $120,000, Inventory in the amount of $1,374,618 $652,906 December 31, 2016 2015, See Note 3.

Note 9 - Property and Equipment

Note 9 - Property and Equipment	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	9 . Property and Equipment The major classes of property and equipment are as follows: Useful Life (in years) 2016 2015 Production machinery and equipment 5 $ 810,996 $ 1,075,216 Other machinery and equipment, primarily computers and research equipment 3 – 5 407,201 421,318 Furniture and fixtures 7 645,922 648,131 Software 3 470,669 476,530 Leasehold improvements* Term of Lease 897,584 897,584 Total $ 3,232,372 $ 3,518,779 * We amortize leasehold improvements over the term of the lease, which in all cases is shorter than the estimated useful life of the asset. Property and equipment includes $9,000 $7,000 December 31, 2015. No December 31, 2016. 2016, 2015 2014, $496,000, $562,000 $488,000, Property and equipment, net of accumulated amortization, in the amount of $70,973 $151,412 December 31, 2016 2015, See Note 3.

Note 10 - Investment in Macroph

Note 10 - Investment in Macrophage Therapeutics, Inc.	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Investments in and Advances to Affiliates, Schedule of Investments [Text Block]	10 . Investment in Macrophage Therapeutics, Inc. In March 2015, 50 “MT Preferred Stock”) and warrants to purchase up to 1,500 $50,000 one 30 40% 50 may 1% March 11, 2015, first 10 300 $500,000. The warrants have certain characteristics including a net settlement provision that require the warrants to be accounted for as a derivative liability at fair value, with subsequent changes in fair value included in earnings. The fair value of the warrants was estimated to be $63,000 December 31, 2015. 1 4. $46,000 $2.0 $113,000 In addition, we entered into a Securities Exchange Agreement with the MT Investors providing them an option to exchange their MT Preferred Stock for our common stock in the event that MT has not $50 second $50,000 80% twenty second $3.00. not $58,320 In December 2015 May 2016, $200,000 not During the year ended December 31, 2016, $200,000 In July 2016, ’s Board of Directors authorized modification of the original investments of $300,000 $200,000 10% $500 first $200,000 December 2015 May 2016. 10 not

Note 11 - Investment in R-NAV,

Note 11 - Investment in R-NAV, LLC	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Equity Method Investments and Joint Ventures Disclosure [Text Block]	1 1 . Investment in R-NAV, LLC In July 2014, d Navidea’s proprietary Manocept CD206 117m Both Rheumco and Navidea contributed licenses for intellectual property and technology to R-NAV in exchange for common units in R-NAV. The contributions of these licenses were recorded using the carryover basis. R-NAV was initially capitalized through a $4.0 third $1.0 three $333,334 $666,666, two first second A principal payment of $333,333 July 2015. 3,500,000 1,000,000 500,000 Navidea initially owned approximately 33.7% December 31, 2015, ed approximately 27.3% not three $10.5 3 Effective May 31, 2016, 1 1,500,000 3,500,000 2 $110,000 1 2 $333,333 $39,732 2016. Navidea ’s investment in R-NAV was being accounted for using the equity method of accounting. In accordance with current accounting guidance, the Company's initial contributions of cash and note payable totaling $1.0 $727,000 $273,000 $15,159, $305,253 $523,809 December 31, 2016, 2015 2014, $0 May 31, 2016. The Company ’s obligation to provide $500,000 $15,000, $64,000 $39,000 December 31, 2016, 2015 2014, May 31, 2016, $383,000 May 31, 2016 Navidea provided additional services to R-NAV in support of its development activities. Such services were immaterial to Navidea ’s overall operations. See Note 13.

Note 12 - Accounts Payable, Acc

Note 12 - Accounts Payable, Accrued Liabilities and Other	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	1 2 . Accounts Payable, Accrued Liabilities and Other Accounts payable at December 31, 2016 2015 $116,000 $7,000, Accrued liabilities and other, including an aggregate of $106,000 $83,000 December 31, 2016 2015, 2016 2015 Interest $ 5,756,519 $ 478 Contracted services 1,194,678 1,636,167 Compensation 624,345 440,879 Royalties 663 275 Other 281,651 101,549 Total $ 7,857,856 $ 2,179,348 Accounts payable in the amount of $1,957,938 $242,220 December 31, 2016 2015, Accrued liabilities in the amount of $607,659 $859,365 December 31, 2016 2015, 3.

Note 13 - Notes Payable

Note 13 - Notes Payable	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Debt Disclosure [Text Block]	1 3 . Notes Payable Platinum In July 2012, p to $50 Tc99m $35 $15 June 25, 2013, $8.0 In June 2013, “First Platinum Amendment”). Concurrent with the execution of the First Platinum Amendment, the Company delivered an Amended and Restated Promissory Note (the “First Amended Platinum Note”) to Platinum, which amended and restated the original promissory note issued to Platinum, in the principal amount of up to $35 6.75%; 10%; 0.125%. two 90% 10 10 $2.0 Tc99m Also in connection with the First Platinum Amendment, the Company and Platinum entered into a Warrant Exercise Agreement ( “Exercise Agreement”), pursuant to which Platinum exercised its Series X $4.8 2,364.9 7,733,223 3,270 In March 2014, second “Second Platinum Amendment”). Concurrent with the execution of the Second Platinum Amendment, the Company delivered an Amended and Restated Promissory Note (the “Second Amended Platinum Note”) to Platinum, which amended and restated the First Amended Platinum Note. The Second Amended Platinum Note adjusted the interest rate to the greater of (i) the United States prime rate as reported in The Wall Street Journal plus 6.75%, 10.0%, 0.125%. In May 2015, “Third Platinum Amendment”). Among other things, the Third Platinum Amendment (i) extended the term of the Platinum Loan Agreement until a date six 6.75%, 10.0% 0.125%; not ten $2.53 The Platinum Note is reflected on the consolidated balance sheets at its principal balance plus the estimated fair value of the embedded conversion option of $153,000 December 31, 2016. During the years ended December 31, 2016, 2015 2014, $2.9 $615,000 $1.3 $9.6 $11.5 December 31, 2016 2015, The Platinum Loan Agreement carries standard non-financial covenants typical for commercial loan agreements, many of which are similar to those contained in the CRG Loan Agreement, that impose significant requirements on us. Our ability to comply with these provisions may ’s alleged claims do not not The Platinum Loan Agreement, as amended, provides us with a credit facility of up to $50 $4.5 $4.0 December 31, 2015 2013. not s ended December 31, 2016 2014. $1.0 $761,000 December 31, 2016 2015, 16 6%, July 1, 2016. December 31, 2016, $9.5 $7.7 $1.8 $27.3 $15 15 In connection with the closing of the Asset Sale to Cardinal Health 414 March 2017, $7.7 $1.9 not Capital Royalty Partners II, L.P. In May 2015, $50 $10 May 15, 2015 ( 14.0%. March 31, 2019, 10.00% 4.00% 2016 2015, $553,000 $1.3 June 30, 2015. eight two March 31, 2021. Pursuant to a notice of default letter sent to Navidea by CRG in April 2016, second 2016 December 31, 2016 2015, $5.8 $0, December 31, 2016 2015, $51.7 $51.3 In connection with the CRG Loan Agreement, the Company recorded a debt discount related to lender fees and other costs directly attributable to the CRG Loan Agreement totaling $2.2 $1.0 $1.0 second 2016. The CRG Term Loan was collateralized by a security interest in substantially all of the Company's assets. In addition, the CRG Loan Agreement required that the Company adhere to certain affirmative and negative covenants, including financial reporting requirements and a prohibition against the incurrence of indebtedness, or creation of additional liens, other than as specifically permitted by the terms of the CRG Loan Agreement. The Lenders could accelerate the payment terms of the CRG Loan Agreement upon the occurrence of certain events of default set forth therein, which include the failure of the Company to make timely payments of amounts due under the CRG Loan Agreement, the failure of the Company to adhere to the covenants set forth in the CRG Loan Agreement, and the insolvency of the Company. The covenants of the CRG Loan Agreement included a covenant that the Company shall have EBITDA of no $5 Tc99m $22.5 2016, $45 2020. 2.5 $5 14% 18% During the course of 2016, June 22, 2016, one $4.1 $3.9 $189,000 2016 2017. On March 3, 2017, 414 February 22, 2017. March 3, 2017, the $59 no no $47 no $66 414 $7 414’s $12 one 414 414 $59 first 414, 414 414 414 414, 414 $2 $3 March 3, 2017, 414 $7 March 7, 2017, $12 July 3, 2017. 4, 14 25 Oxford Finance, LLC In March 2014, “Oxford Loan Agreement”) with Oxford Finance, LLC (“Oxford”), providing for a loan to the Company of $30 1 $30 8.5% 2 391,032 $1.918 March 2021 ( $3.0 $120,000, $2.4 We began making monthly payments of interest only on April 1, 2014, April 1, 2015. May 2015, $31.7 $289,000 $2.4 December 31, 201 5, no December 31, 2016. General Electric Capital Corporation/MidCap Financial SBIC, LP In June 2013, “GECC/MidCap Loan Agreement”) with General Electric Capital Corporation (“GECC”) and MidCap Financial SBIC, LP (“MidCap”), pursuant to which we issued GECC and MidCap: ( 1 $25 9.83%, 2 301,205 $2.49 June 2023 ( June 25, 2013 June 30, 2014. 30 first one December 23, 2016. 4.0% The Company recorded a debt discount related to the issuance of the Series HH Warrants and other fees to the lenders totaling $1.9 $881,000. $1.0 In March 2014, $26.7 $500,000 $1.0 $2.6 December 31, 201 4, no December 31, 2016. R-NAV, LLC In July 2014, $666,666, two July 15, 2015 July 15, 2016, first second ore interest at 0.31% $333,333 July 2015. Effective May 31, 2016, 1 1,500,000 3,500,000 2 $110,000 1 2 $333,333 1 1. I PFS Corporation In December 2016, we prepaid $348,000 8.99%. eight $45,000, July 10, 2017. December 31, 2016 Summary During the years ended December 31, 201 6, 2015 2014, $5,000, $1.3 $3.4 $326,000 $844,000, December 31, 2015 2014. Interest expense in the amount of $14,856,404, $5,603,820 $326,337 December 31, 2016, 2015 2014, See Note 3. Annual principal maturities of our notes payable are $ 52.0 $0, $0, $0, $9.5 $0 2017, 2018, 2019, 2020, 2021

Note 14 - Commitments and Conti

Note 14 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	1 4 . Commitments and Contingencies We are subject to legal proceedings and claims that arise in the ordinary course of business. Section 16 On August 12, 2015, two 16 1934, ’s common stock by the Platinum funds, and seeking disgorgement of the short-swing profits realized by the funds (the “Litigation”). The Company was named as a nominal defendant in the Litigation. The Litigation was resolved on the terms set forth in a settlement agreement (the “Settlement Agreement”). The Settlement Agreement was subject to a pending joint motion for approval. The Court approved the settlement on Friday, July 1, 2016. 6% 8.125% July 1, 2016. Sinotau Litigation – NAV4694 On August 31, 2015, Sinotau”) filed a suit for damages, specific performance, and injunctive relief against the Company in the United States District Court for the District of Massachusetts alleging breach of a letter of intent for licensing to Sinotau of the Company’s NAV4694 September 2016, not In July 2016, Cerveau”) as a designated party for the rights resulting from the relationship between Navidea and Sinotau. The term sheet outlined the terms of a potential agreement between the parties to sublicense NAV4694 NAV4694 60 no NAV4694 CRG Litigation During the course of 2016, June 22, 2016, one ’s primary bank accounts and took possession of $4.1 $3.9 $189,000 2016 2017. On March 3, 2017, 414 February 22, 2017. March 3, 2017, $59 no no $47 no $66 414 $7 ’s cost and expense to be deducted from the closing proceeds due to the Company, and subject to Cardinal Health 414’s $12 one 414 414 $59 first 414, 414 414 414 414, 414 $2 $3 March 3, 2017, 414 $7 March 7, 2017, $12 The Texas hearing is currently set for July 3, 2017. 4, 13 25 Former CEO Arbitration On May 12, 2016 ’s then Chief Executive Officer, claiming that he was terminated without cause and, alternatively, that he resigned in accordance with Section 4G May 9, 2016. May 13, 2016, 4G no A three April 3- 7, 2017 Former Director Litigation On August 12, 2016, The litigation was dismissed without prejudice on December 19, 2016. FTI Consulting, Inc. Litigation On October 11, 2016, $782,600 $730,264 $52,337 ’ fees, costs and expenses. On November 14, 2016, February 7, 2017, August 31, 2017 Discovery will commence within the next few weeks. The Company intends to vigorously defend the action. Sinotau Litigation – Tc99m T ilmanocept On February 1, 2017, The Company's complaint included claims seeking a declaration of the rights and obligations of the parties to an agreement regarding rights for the Tc 99m 414. February 3, 2017, March 6, 2017. March 3, 2017. March 6, not Sinotau also filed a suit against the Company and Cardinal Health 414 February 2, 2017. On February 18, 2017, 414 March 1, 2017, In accordance with ASC Topic 450, Contingencies not

Note 15 - Preferred Stock

Note 15 - Preferred Stock	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Preferred Stock [Text Block]	1 5 . Preferred Stock As discussed in Note 1 3, June 2013, X 2,364.9 7,733,223 During 2013, 1,737.9 5,682,933 2014, 4,422 14,459,940 November 2014, second latinum exchanged 4,499,520 1,376 In August 2015, two 4,519 twenty 3,270 14,777,130 $0.01 14,777,130 no $1.35. no No one no

Note 16 - Equity Instruments

Note 16 - Equity Instruments	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	1 6 . Equity Instruments a. Stock Warrants: December 31, 2016, 11.3 $0.01 $3.04 $0.33. 25 The following table summarizes information about our outstanding warrants at December 31, 2016: Exercise Price Number of Warrants Expiration Date Series BB $ 2.00 300,000 July 2018 Series HH 2.49 301,205 June 2023 Series II 3.04 275,000 June 2018 Series KK 1.918 391,032 March 2021 Series LL 0.01 9,777,130 August 2035 Series MM 2.50 150,000 September 2019 Series MM 2.50 150,000 October 2019 Total $ 0.33 * 11,344,367 * Weighted average exercise price. In addition, at December 31, 2016, 300 $2,000 In March 2014, Warrants to purchase an aggregate of 391,032 $1.918 March 2021. In November 2014, an outside investor exchanged their Series JJ warrants for 3,843,223 $7.7 In July 2015, three July 2018. $150,000 third 2015. In September 2015, four 150,000 $2.50 “Chardan”). In October 2015, four 150,000 $2.50 $256,000 third 2015. In October 2015, 5,000,000 Warrants were exercised on a cashless basis in exchange for the issuance of 4,977,679 c. Common Stock Reserved: December 31, 2016, 18,641,776

Note 17 - Reductions in Force

Note 17 - Reductions in Force	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	1 7 . Reductions in Force In May 2014, ’s Board of Directors made the decision to refocus the Company's resources to better align the funding of our pipeline programs with the expected growth in Tc99m 11 Effective May 30, 2014, $750,000 two June 9, 2014, January 2, 2015, Effective June 1, 2014, December 31, 2014 $27,500 40,000 Dr. Pykett terminated the Consulting Agreement effective September 8, 2014. December 1, 2014 $94,000 December 31, 2014 . During the year ended December 31, 2014, $557,000 not The Company appointed Michael M. Goldberg, M.D., as interim Chief Executive Officer effective May 30, 2014. then served as a member of the Board of Directors of the Company and did not $15,000 December 31, 2014, $53,000. October 13, 2014. In March 2015, second seven three During the year ended December 31, 2015, $1.3 d actual and estimated separation costs as well as the impact of accelerated vesting or forfeiture of certain equity awards resulting from the separation of $273,000. The remaining accrued separation costs of $0 $9,000 December 31, 2016 2015,

Note 18 - Income Taxes

Note 18 - Income Taxes	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Income Tax Disclosure [Text Block]	1 8 . Income Taxes As of December 31, 201 6 2015, $79.1 $74.2 As of December 31, 2016 2015 Deferred tax assets: Net operating loss carryforwards $ 66,150,646 $ 60,129,827 R&D credit carryforwards 9,729,673 9,465,900 Stock compensation 1,368,458 1,898,394 Intangibles 1,720,761 1,921,934 Temporary differences 132,476 801,002 Deferred tax assets before valuation allowance 79,102,014 74,217,057 Valuation allowance (79,102,014 ) (74,217,057 ) Net deferred tax assets $ — $ — Current accounting standards require a valuation allowance against deferred tax assets if, based on the weight of available evidence, it is more likely than not may not December 31, 2016 2015. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not not Based upon the level of historical taxable income and projections for future taxable income over the periods in which the deferred tax assets are deductible, management believes it is more likely than not not December 31, 2016. As of December 31, 2016 2015, $193.3 $177.6 million, respectively. Of those amounts, $15.3 December 31, 2016 2015, not As of December 31, 2016 2015, $28.2 $24.7 2032. At December 31, 201 6 2015, $9.4 $9.1 There were no U.S. net operating loss carryforwards or R&D credit carryforwards during 2016 2015. As of December 31, 2016 Generated Expiration U.S. Net Operating Loss Carryforwards U.S. R&D Credit Carryforwards 1998 2018 $ 17,142,781 $ 1,173,387 1999 2019 — 130,359 2000 2020 — 71,713 2001 2021 — 39,128 2002 2022 1,282,447 5,350 2003 2023 337,714 2,905 2004 2024 1,237,146 22,861 2005 2025 2,999,083 218,332 2006 2026 3,049,735 365,541 2007 2027 2,842,078 342,898 2008 2028 2,777,503 531,539 2009 2029 13,727,950 596,843 2010 2030 5,397,680 1,094,449 2011 2031 1,875,665 1,950,744 2012 2032 28,406,659 468,008 2013 2033 37,450,522 681,772 2014 2034 34,088,874 816,116 2015 2035 25,073,846 492,732 2016 2036 15,581,209 358,404 Total carryforwards $ 193,270,891 $ 9,363,081 The credit for certain research and experimentation expenses expired at the end of 2014. 2015 December 18, 2015. During the years ended December 31, 2016, 2015 2014, $13,000, $11,000 $15,000, As of December 31, 2016 2015, $7.7 $7.6 not December 31, 2016 2015. Under Sections 382 383 1986, may 382 2013 not 382 ’s net operating loss and R&D tax credit carryforwards. Reconciliations between the statutory federal income tax rate and our effective tax rate for continuing operations are as follows: Years Ended December 31, 2016 2015 2014 Amount % Amount % Amount % Benefit at statutory rate $ (2,508,264 ) (34.0 )% $ (7,835,163 ) (34.0 )% $ (10,322,016 ) (34.0 )% Adjustments to valuation allowance 2,354,656 31.9 % 8,212,163 35.7 % 11,046,650 36.4 % Adjustments to R&D credit carryforwards (239,049 ) (3.2 )% (612,087 ) (2.7 )% (340,886 ) (1.1 )% Disqualified debt interest 188,060 2.5 % 438,007 1.9 % — 0.0 % Permanent items and other 204,597 2.8 % (202,920 ) (0.9 )% (383,748 ) (1.3 )% Benefit per financial statements $ — $ — $ — Certain revenue and expense amounts in the years ended December 31, 2016, 2015 2014 See Note 3.

Note 19 - Segments

Note 19 - Segments	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	1 9 . Segments We report information about our operating segments using the “management approach” in accordance with current accounting standards. This information is based on the way management organizes and reports the segments within the enterprise for making operating decisions and assessing performance. Our reportable segments are identified based on differences in products, services and markets served. There were no 2015, first 2015, two Tc99m May 31, 2016), NAV4694 NAV5001 April 2015), The information in the following tables is derived directly from each reportable segment ’s financial reporting. December 31, 2016 2015 See Note 3. Year Ended December 31, 2016 Diagnostics Therapeutics Corporate Total Tc99m tilmanocept sales revenue: United States $ — $ — $ — $ — International 39,601 — — 39,601 Tc99m tilmanocept license revenue 1,795,625 — — 1,795,625 Grant and other revenue 3,011,642 124,766 — 3,136,408 Total revenue 4,846,868 124,766 — 4,971,634 Cost of goods sold, excluding depreciation and amortization 62,260 — — 62,260 Research and development expenses, excluding depreciation and amortization 6,375,929 762,151 — 7,138,080 Selling, general and administrative expenses, excluding depreciation and amortization ( a ) — 63,158 7,403,329 7,466,487 Depreciation and amortization ( b ) 56,317 — 397,232 453,549 Income (loss) from operations ( c ) (1,647,638 ) (700,543 ) (7,800,561 ) (10,148,742 ) Other income (expense), excluding equity in the loss of R-NAV, LLC ( d ) — — 2,786,007 2,786,007 Equity in the loss of R-NAV, LLC — — (15,159 ) (15,159 ) Net loss from continuing operations (1,647,638 ) (700,543 ) (5,029,713 ) (7,377,894 ) Loss from discontinued operations, net of tax effect (6,931,137 ) — — (6,931,137 ) Net income (loss) (8,578,775 ) (700,543 ) (5,029,713 ) (14,309,031 ) Total assets, net of depreciation and amortization: United States $ 3,815,271 $ 15,075 $ 8,498,797 $ 12,329,143 International 131,752 — 781 132,533 Capital expenditures — — 1,847 1,847 Year Ended December 31, 2015 Diagnostics Therapeutics Corporate Total Tc99m tilmanocept sales revenue: United States $ — $ — $ — $ — International 19,075 — — 19,075 Tc99m tilmanocept license revenue 1,133,333 — — 1,133,333 Grant and other revenue 1,860,953 — — 1,860,953 Total revenue 3,013,361 — — 3,013,361 Cost of goods sold, excluding depreciation and amortization 3,226 — — 3,226 Research and development expenses, excluding depreciation and amortization 9,831,834 730,895 — 10,562,729 Selling, general and administrative expenses, excluding depreciation and amortization ( a ) — 123,884 10,242,066 10,365,950 Depreciation and amortization (b ) 232,091 — 290,105 522,196 Loss from operations ( c ) (7,053,790 ) (854,779 ) (10,532,171 ) (18,440,740 ) Other income (expense), excluding equity in the loss of R-NAV, LLC ( d ) — — (4,298,604 ) (4,298,604 ) Equity in the loss of R-NAV, LLC — — (305,253 ) (305,253 ) Net loss from continuing operations (7,053,790 ) (854,779 ) (15,136,028 ) (23,044,597 ) Income from discontinued operations, net of tax effect ( e ) (5,713,598 ) — 1,194,660 (4,518,938 ) Net loss (12,767,388 ) (854,779 ) (13,941,368 ) (27,563,535 ) Total assets, net of depreciation and amortization: United States $ 4,161,029 $ — $ 10,391,805 $ 14,552,834 International 410,666 — 1,013 411,679 Capital expenditures 26,589 — 12,412 39,001 (a) General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not ( b ) Depreciation and amortization is reflected in research and development ( $0 $10,617 December 31, 2016 2015, $397,232 $460,839 December 31, 2016 2015, ( c ) Loss from operations does not ( d ) Amounts consist primarily of interest income, interest expense, changes in fair value of financial instruments, and losses on debt extinguishment, which are not ( e ) Amount not 2015 2011 1

Note 20 - Agreements

Note 20 - Agreements	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Significant Agreements Disclosure [Text Block]	20 . Agreements a. Supply Agreements: November 2009, Tc99m ten November 2019 three not 60 $1.1 $225,000 $300,000 December 31, 2016, 2015 2014, December 31, 2016, $525,000 Tc99m 2017. 414, 414. In May 2013, NAV5001 three d in May 2016 August 2014, March 2016, $43,000, $244,000 $505,000 December 31, 2016, 2015 2014, In August 2013, NAV4694. three d in August 2016 not $826,000, $855,000 $2.2 December 31, 2016, 2015 2014, In September 2013, Tc99m not 60 Tc99m $1.2 $472,000 $96,000 December 31, 2016, 2015 2014, December 31, 2016, $562,000 2017. 414, 414. Also in September 2013, s an initial term of three one six may 60 may not 30 $149,000, $677,000 $272,000 December 31, 2016, 2015 2014, December 31, 2016, $1,500 2017. Tc99m b. Research and Development Agreements: January 2002, Tc99m July 2014, license agreement to extend the agreement until the third $25,000 $25,000 $25,000 Tc99m $2,000, $1,000 $1,000 2016, 2015 2014, Tc99m In connection with the March 2017 the Asset Sale to Cardinal Health 414, Tc99m 414 414 414 five 5 1 $.001 $1.50 25 In April 2008, second Tc99m The license agreement was effective until the expiration date of the longest-lived underlying patent. Under the terms of the license agreement, UCSD granted us the exclusive rights to make, use, sell, offer for sale and import licensed products as defined in the agreement and to practice the defined licensed methods during the term of the agreement. We could also sublicense the patent rights, subject to certain sublicense terms as defined in the agreement. In consideration for the license rights, we agreed to pay UCSD a license issue fee of $25,000 $25,000 $25,000 Tc99m $25,000 2014, Tc99m July 2014. In July 2014, Tc99m than Tc99m third may $25,000 $25,000 $25,000 $199,000, $152,000 $25,000 2016, 2015 2014, In December 2011, 4694, tenth first NAV4694 NAV4694 $5.0 $6.5 $11.0 $116,000, $80,000 $81,000 2016, 2015 2014, In July 2012, NAV5001, 123 ’s disease and other movement disorders, with a potential use as a diagnostic aid in dementia. Under the terms of the sublicense agreement, Alseres granted Navidea an exclusive, worldwide sublicense to research, develop and commercialize NAV5001. one $175,000 300,000 $2.9 $2.5 1.15 950,000 not April 2015, NAV5001 March 1, 2015. NAV5001 $5,000 $42,000 2015 2014, c. Employment Agreements: December 31, 2016, two December 31, 2016, 1.3 2.75 December 31, 2016, $1.9

Note 21 - Leases

Note 21 - Leases	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Leases of Lessee Disclosure [Text Block]	2 1 . Leases We lease office space in Ohio under an operating lease that expires in October 2022. March 2017, March 2018. As of December 31, 2016, December 31 Operating Leases 2017 $ 277,946 2018 284,246 2019 290,734 2020 297,405 2021 304,201 Thereafter 253,339 Total $ 1,707,871 Total rental expense was $187,000, $217,000 $357,000 December 31, 2016, 2015 2014,

Note 22 - Employee Benefit Plan

Note 22 - Employee Benefit Plan	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	2 2 . Employee Benefit Plan We maintain an employee benefit plan under Section 401 may, not ’s contribution with our common stock, up to a defined maximum. We also pay certain expenses related to maintaining the plan. We recorded expenses related to our 401 $47,000, $73,000 $83,000 2016, 2015 2014,

Note 23 - Supplemental Disclosu

Note 23 - Supplemental Disclosure for Statements of Cash Flows	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Cash Flow, Supplemental Disclosures [Text Block]	2 3 . Supplemental Disclosure for Statements of Cash Flows During 201 6, 2015 2014, $5.5 $4.6 $2.9 2016 $778,000 $2.1 2016, 2015, 2014, 67,002, 68,157 36,455 401 $121,000, $117,000 $100,000, December 2016, $348,000 8.99%. 2015 2014, $1.0 $2.4 In connection with their initial investment in March 2015, $63,000. $46,000 See Note 10. During 2014, $465,000. 2014, $666,666, two July 15, 2015 July 15, 2016, first second 11.

Note 24 - Selected Quarterly Fi

Note 24 - Selected Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Quarterly Financial Information [Text Block]	2 4 . Selected Quarterly Financial Data (Unaudited) Quarterly financial information for fiscal 2016 2015 December 31, 2016 2015 See Note 3. For the Quarter Ending March 31 June 30 September 30 December 31 2016: Tc99m tilmanocept sales revenue $ 9 $ 4 $ 18 $ 9 Tc99m tilmanocept license revenue 254 246 1,296 — Grant and other revenue 686 917 511 1,022 Gross profit 947 1,166 1,821 975 Operating expenses 4,705 3,407 2,731 4,215 Loss from operations (3,758 ) (2,241 ) (910 ) (3,240 ) Loss from continuing operations (2,682 ) (817 ) (1,761 ) (2,118 ) Gain (l oss) from discontinued operations, net of tax (1,004 ) (5,865 ) 1,702 (1,764 ) Net loss attributable to common stockholders (3,686 ) (6,681 ) (59 ) (3,882 ) Loss per common share (basic and diluted) (1) Continuing operations $ (0.02 ) $ 0.00 $ (0.01 ) $ (0.01 ) Discontinued operations $ 0.00 $ (0.04 ) $ 0.01 $ (0.01 ) Attributable to common stockholders $ (0.02 ) $ (0.04 ) $ (0.00 ) $ (0.02 ) 2015: Tc99m tilmanocept sales revenue $ 4 $ — $ 9 $ 6 Tc99m tilmanocept license revenue 83 250 550 250 Grant and other revenue 190 654 477 540 Gross profit 276 904 1,034 796 Operating expenses 6,900 4,348 5,947 4,256 Loss from operations (6,623 ) (3,443 ) (4,912 ) (3,463 ) Loss from continuing operations (5,983 ) (8,171 ) (6,509 ) (1,946 ) Loss from discontinued operations, net of tax (1,309 ) (1,520 ) (1,562 ) (564 ) Net loss attributable to common stockholders (7,337 ) (9,691 ) (8,071 ) (2,510 ) Loss per common share (basic and diluted) (1) Continuing operations $ (0.04 ) $ (0.05 ) $ (0.04 ) $ (0.02 ) Discontinued operations $ (0.01 ) $ (0.01 ) $ (0.01 ) $ 0.00 Attributable to common stockholders $ (0.05 ) $ (0.06 ) $ (0.05 ) $ (0.02 ) ( 1 Net loss per share is computed independently for each of the quarters presented. Therefore the sum of the quarterly per-share calculations will not

Note 25 - Subsequent Events

Note 25 - Subsequent Events	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Subsequent Events [Text Block]	2 5 . Subsequent Events: a. Closing on the Asset Sale to Cardinal Health 414: On March 3, 2017, November 23, 2016 414 414 ® In exchange for the Acquired Assets, Cardinal Health 414 $80.6 $3 below, (ii) assumed certain liabilities of the Company associated with the Product as specified in the Purchase Agreement, and (iii) agreed to make periodic earnout payments (to consist of contingent payments and milestone payments which, if paid, will be treated as additional purchase price) to the Company based on net sales derived from the purchased Product subject, in each case, to Cardinal Health 414’s no $230 ten $20.1 three $3 414 Upon closing of the Asset Sale, the Supply and Distribution Agreement between Cardinal Health 414 no 414 $1.2 ng date, net of prior payments. In connection with the closing of the Asset Sale, the Company entered into a License-Back Agreement (the “License-Back”) with Cardinal Health 414. 414 414 not ’s compliance with certain restrictions in the License-Back, the License-Back also restricts Cardinal Health 414 1 2 414 first 414 As part of the Asset Sale, the Company and Cardinal Health 414 The Company amended and restated its Tc99m 414 414 414 Pursuant to the Purchase Agreement, the Company granted to each of Cardinal Health 414 five 5 10 1 ’s common stock, par value $.001 $1.50 Prior to the Asset Sale, the Company had no 414 414 ’s primary distributor of the Product throughout the United States pursuant to the Supply and Distribution Agreement which, as set forth above, was terminated as of the closing of the Asset Sale. Post-closing and after paying off our outstanding indebtedness and transaction-related expenses, Navidea has approximately $15.6 $3.7 4694 414 ’s financial position and ability to continue as a going concern has been removed. b. CRG Litigation and Settlement: On February 9, 2017, one May 8, 2015, 11.01 4.05 May 8, 2015, not By letter dated February 21, 2017 ( CRG Loan Documents, including, without limitation, pursuant to Sections 4.01 4.13 5.04 11.02 12.03 Tc99m March 13, 2017. January 31, 2017, $63,198,774.46 January 31, 2017 12.03 12.03 January 31, 2017) not may not On March 3, 2017, 414 February 22, 2017. March 3, 2017, the $59 no $59 March 3, 2017, no $47 no $66 414 $7 414’s $12 one 414 414 $59 first 414, 414 414 414 414, 414 $2 $3 March 3, 2017, 414 $7 March 7, 2017, $12 July 3, 2017. 13. c. Platinum Note Payment : $7.7 $1.9 not 13. d. Series LL Warrant Exercise: January 17, 2017, 5,411,850 $54,119. 16

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Nature of Operations [Policy Text Block]	a. Organization and Nature of Operations: Navidea ’s Manocept platform is predicated on the ability to specifically target the CD206 ® Tc99m first Tc99m On March 3, 2017, November 23, 2016, ( 414, 414” ’s radioactive diagnostic agent marketed under the Lymphoseek ® Upon closing of the Asset Sale, the Supply and Distribution Agreement, dated November 15, 2007 ( 414 no The Asset Sale to Cardinal Health 414 March 2017 Our consolidated balance sheets and statements of operations have been reclassified, as required, for all periods presented to reflect the Business as a discontinued operation. Cash flows associated with the operation of the Business have been combined with operating, investing and financing cash flows, as appropriate, in our consolidated statements of cash flows. Other than Tc99m none In January 2015, From our inception through August 2011, “GDS Business”). We sold the GDS Business to Devicor Medical Products, Inc. (“Devicor”) in August 2011. $30.3 $20 2017. $759,000, 2015 2015 $1.2 $436,000 2015. not 2015 2016. In December 2001, August 2009, ’s Board of Directors decided to discontinue the operations and attempt to sell Cardiosonix. However, we were obligated to continue to service and support the Cardiosonix devices through 2013. not In July 2011, Tc99m 100%
Consolidation, Policy [Policy Text Block]	b. Principles of Consolidation: May 2016, not 11.
Use of Estimates, Policy [Policy Text Block]	c. Use of Estimates:
Fair Value of Financial Instruments, Policy [Policy Text Block]	d. Financial Instruments and Fair Value: 1 3 three Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2 – Quoted prices in markets that are not Level 3 – Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. A financial instrument ’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. In determining the appropriate levels, we perform a detailed analysis of the assets and liabilities whose fair value is measured on a recurring basis. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no 3. 4. The following methods and assumptions were used to estimate the fair value of each class of financial instruments: ( 1 Cash, restricted cash, accounts and other receivables, accounts payable, and accrued liabilities: The carrying amounts approximate fair value because of the short maturity of these instruments. At December 31, 2016, 13. December 31, 2016, $894,000 December 31, 2016. ( 2 Notes payable: The carrying value of our debt at December 31, 201 6 2015 December 31, 2016 2015, 3 December 31, 2016 2015, $153,000 $3.0 4 13. ( 3 Derivative liabilities: Derivative liabilities are related to certain outstanding warrants which are recorded at fair value. Derivative liabilities totaling $63,000 December 31, 2016 2015 December 31, 2016 2015 4.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	e. Stock-Based Compensation: December 31, 2016, two 2002 “2002 2014 “2014 2014 may may 12 5 2002 no may Stock options granted under the 2002 2014 one four not ten 90 ’s separation from employment with the Company. We issue new shares of our common stock upon exercise of stock options. In September 2016, 2016 “2016 10 2016 not ’s stockholders. In connection with Dr. Goldberg’s appointment as Chief Executive Officer of the Company in September 2016, 5,000,000 2016 100% five $2.50 tenth Stock-based payments to employees and directors, including grants of stock options, are recognized in the consolidated statement of operations based on their estimated fair values. The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. Expected volatilities are based on the Company ’s historical volatility, which management believes represents the most accurate basis for estimating expected future volatility under the current circumstances. Navidea uses historical data to estimate forfeiture rates. The expected term of stock options granted is based on the vesting period and the contractual life of the options. The risk-free rate is based on the U.S. Treasury yield in effect at the time of the grant. The assumptions used to calculate the fair value of stock option awards granted during the years ended December 31, 2016, 2015 2014 2016 2015 2014 Expected volatility 59% - 75% 61% - 64% 61% - 67% Weighted-average volatility 60% 62% 65% Expected dividends — — — Expected term (in years) 5.0 - 6.0 5.1 - 6.3 5.3 - 7.4 Risk-free rate 1.2% - 1.8% 1.5% - 1.9% 1.6% - 2.0% The portion of the fair value of stock-based awards that is ultimately expected to vest is recognized as compensation expense over either ( 1 2 may ’s estimates of the probable dates of the vesting events. Stock-based awards that do not not 5.
Cash and Cash Equivalents, Policy [Policy Text Block]	f. Cash and Cash Equivalents: 3
Receivables, Policy [Policy Text Block]	g. Accounts and Other Receivable s : 7.
Inventory, Policy [Policy Text Block]	h. Inventory: first first 8.
Property, Plant and Equipment, Policy [Policy Text Block]	i. Property and Equipment: 9.
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	j. Intangible Assets: 5 15 no
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	k. Impairment or Disposal of Long-Lived Assets: may not No December 31, 2016, 2015 2014.
Lessee, Leases [Policy Text Block]	l. Leases: not 21.
Derivatives, Policy [Policy Text Block]	m. Derivative Instruments: not one one not
Revenue Recognition, Policy [Policy Text Block]	n . Revenue Recognition: Prior to the Asset Sale to Cardinal Health 414 March 2017, no may We earned additional revenues based on a percentage of the actual net re venues achieved by Cardinal Health 414 414 414, 414. December 31, 2016 2015, 99% 414. 414 December 31, 2016, 2015 2014 3. We also earn revenues related to our licensing and distribution agreements. The terms of these agreements may not $2.0 March 2015. not not not two $417,000 September 2016, We generate additional revenue from grants to support various product dev elopment initiatives. We generally recognize grant revenue when expenses reimbursable under the grants have been paid and payments under the grants become contractually due. Lastly, we recognized revenues from the provision of services to R-NAV and its subsidiaries through the termination of the R-NAV joint venture on May 31, 2016. 11.
Research and Development Expense, Policy [Policy Text Block]	o . Research and Development Costs:
Income Tax, Policy [Policy Text Block]	p. Income Taxes: December 31, 2016 2015. Current accounting standards include guidance on the accounting for uncertainty in income taxes recognized in the financial statements. Such standards also prescribe a recognition threshold and measurement model for the financial statement recognition of a tax position taken, or expected to be taken, and provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company believes that the ultimate deductibility of all tax positions is highly certain, although there is uncertainty about the timing of such deductibility. As a result, no December 31, 201 6 2015 not twelve December 31, 2016, 2013 2016 18.
New Accounting Pronouncements, Policy [Policy Text Block]	q . Change in Accounting Principle: April 2015, No. 2015 03, Simplifying the Presentation of Debt Issuance Costs 2015 03 not 2015 03. 2015 03 December 15, 2015, 2015 03 2015, 2015 03. December 31, 2016 2015, 2015 03 no In November 2015, No. 2015 17, Balance Sheet Classification of Deferred Taxes 2015 17 2015 17 may 2015 17 December 31, 2015 2015 17 As a result of the Asset Sale, our consolidated balance sheets and statements of operations have been reclassified, for all periods presented to reflect the Business as a discontinued operation, including interest expense related to the CRG and Platinum notes, as required by Accounting Standards Codification 205 20 45 6. r . Recent Accounting Standards: In August 2014, No. 2014 15, Presentation of Financial Statements-Going Concern . ASU 2014 15 2014 15 one 2014 15 December 15, 2016, 2014 15 not In February 2016, No. 2016 02, Leases (Topic 842 . ASU 2016 02 842 2016 02 December 15, 2018, 2016 02 2016 02 In March 2016, ued ASU No. 2016 08, Revenue from Contracts with Customers – Principal versus Agent Considerations (Reporting Revenue Gross versus Net) . ASU 2016 08 not 2016 08 No. 2014 09, Revenue from Contracts with Customers (Topic 606 not 2016 08 2014 09, one No. 2015 14, Revenue from Contracts with Customers – Deferral of the Effective Date . Public business entities should adopt the new revenue recognition standard for annual reporting periods beginning after December 15, 2017, December 15, 2016, 2014 09 may 414 March 2017. In March 2016, No. 2016 09, Compensation – Stock Compensation . ASU 2016 09 2016 09 December 15, 2016, 2016 09 2016 09 In April 2016, No. 2016 10, Revenue from Contracts with Customers – Identifying Performance Obligations and Licensing . ASU 2016 10 not 2016 10 No. 2014 09, Revenue from Contracts with Customers (Topic 606 not 2016 10 2014 09, one No. 2015 14, Revenue from Contracts with Customers – Deferral of the Effective Date . Public business entities should adopt the new revenue recognition standard for annual reporting periods beginning after December 15, 2017, December 15, 2016, 2016 120 may 414 March 2017. In May 2016, No. 2016 12, Revenue from Contracts with Customers – Narrow-Scope Improvements and Practical Expedients . ASU 2016 12 not 606, 2016 12 No. 2014 09, Revenue from Contracts with Customers (Topic 606 not 2016 12 2014 09, one No. 2015 14, Revenue from Contracts with Customers – Deferral of the Effective Date . Public business entities should adopt the new revenue recognition standard for annual reporting periods beginning after December 15, 2017, December 15, 2016, 2016 12 may 414 March 2017. In August 2016, No. 2016 15, Statement of Cash Flows – Classification of Certain Cash Receipts and Cash Payments . ASU 2016 15 2016 15 December 15, 2017, 2016 15 2016 15 2016 15 December 31, 2016. In November 2016, No. 2016 18, Statement of Cash Flows – Restricted Cash . ASU 2016 18 2016 18 December 15, 2017, 2016 18 March 2017, not 2016 18 In December 2016, No. 2016 20, Technical Corrections and Improvements to Topic 606, . ASU 2016 20 not 606, 606, 2016 20 No. 2014 09, Revenue from Contracts with Customers (Topic 606 not 2016 12 2014 09, one No. 2015 14, Revenue from Contracts with Customers – Deferral of the Effective Date . Public business entities should adopt the new revenue recognition standard for annual reporting periods beginning after December 15, 2017, December 15, 2016, 2016 20 may 414 March 2017. In January 2017, No. 2017 01, Business Combinations (Topic 805 . ASU 2017 01 not not not 2017 01 1 2 2017 01 December 15, 2017, 2017 01 No 2017 01. 2017 01

Note 1 - Organization and Sum33

Note 1 - Organization and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2016 2015 2014 Expected volatility 59% - 75% 61% - 64% 61% - 67% Weighted-average volatility 60% 62% 65% Expected dividends — — — Expected term (in years) 5.0 - 6.0 5.1 - 6.3 5.3 - 7.4 Risk-free rate 1.2% - 1.8% 1.5% - 1.9% 1.6% - 2.0%

Note 3 - Discontinued Operati34

Note 3 - Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Disposal Groups, Including Discontinued Operations [Table Text Block]	December 31, 201 6 December 31, 201 5 Accounts and other receivables $ 1,598,994 $ 3,692,747 Inventory, net 1,374,618 652,906 Prepaid expenses 170,635 172,585 Assets associated with discontinued operations, current 3,144,247 4,518,238 Property and equipment, net of accumulated depreciation 70,973 151,412 Patents and trademarks, net of accumulated amortization 34,282 39,473 Assets associated with discontinued operations, noncurrent 105,255 190,885 Total assets associated with discontinued operations $ 3,249,502 $ 4,709,123 Accounts payable $ 1,957,938 $ 242,220 Accrued liabilities 607,659 859,365 Deferred revenue 2,300,000 — Liabilities associated with discontinued operations, current 4,865,597 1,101,585 Other liabilities — 1,000,000 Total l iabilities associated with discontinued operations $ 4,865,597 $ 2,101,585 Years Ended December 31, 2016 2015 2014 Revenue: Lymphoseek sales revenue $ 16,997,497 $ 10,235,277 $ 4,220,753 Royalties on GDS Business — 1,194,660 — Grant and other revenue 575 669 — Total revenue 16,998,072 11,430,606 4,220,753 Cost of goods sold 2,234,780 1,751,537 1,583,519 Gross profit 14,763,292 9,679,069 2,637,234 Operating expenses: Research and development 1,744,496 2,225,004 1,662,611 Selling, general and administrative 5,093,529 6,369,183 6,016,087 Total operating expenses 6,838,025 8,594,187 7,678,698 Income (l oss) from discontinued operations 7,925,267 1,084,882 (5,041,464 ) Interest expense (14,856,404 ) (5,603,820 ) (326,337 ) Loss from discontinued operations $ (6,931,137 ) $ (4,518,938 ) $ (5,367,801 )

Note 4 - Fair Value (Tables)

Note 4 - Fair Value (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	Liabilities Measured at Fair Value on a Recurring Basis as of December 31, 2016 Quoted Prices in Active Markets for Identical Assets and Liabilities Significant Other Observable Inputs Significant Unobservable Inputs (a)(b) Balance as of December 31, Description (Level 1) (Level 2) (Level 3) 2016 Platinum conversion option $ — $ — $ 153,357 $ 153,357 Liability related to MT warrants — — 63,000 63,000 Liabilities Measured at Fair Value on a Recurring Basis as of December 31, 2015 Quoted Prices in Active Markets for Identical Assets and Liabilities Significant Other Observable Inputs Significant Unobservable Inputs (a)(b) Balance as of December 31, Description (Level 1) (Level 2) (Level 3) 2015 Platinum conversion option $ — $ — $ 3,011,880 $ 3,011,880 Liability related to MT warrants — — 63,000 63,000
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	2016 2015 Estimated volatility 76 % 58 % Expected term (in years) 4.75 5.75 Debt rate 8.125 % 14.125 % Beginning stock price $ 0.64 $ 1.33

Note 5 - Stock-based Compensa36

Note 5 - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Year Ended December 31, 2016 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding at beginning of year 5,437,064 $ 1.96 Granted 479,457 1.05 Exercised (50,000 ) 0.27 Canceled and forfeited (2,186,906 ) 1.69 Expired (299,000 ) 2.42 Outstanding at end of year 3,380,615 $ 2.00 6.5 $ 16,013 Exercisable at end of year 2,548,681 $ 2.07 6.1 $ 16,013
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Year Ended December 31, 2016 Number of Shares Weighted Average Grant-Date Fair Value Unvested at beginning of year 361,000 $ 1.69 Granted 168,000 1.20 Forfeited (206,000 ) 1.77 Expired (50,000 ) 1.93 Vested (66,000 ) 1.65 Unvested at end of year 207,000 $ 1.17

Note 6 - Earnings Per Share (Ta

Note 6 - Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Years Ended December 31, 2016 2015 2014 Net loss $ (14,309,031 ) $ (27,563,535 ) $ (35,726,669 ) Less loss attributable to noncontrolling interest (648 ) (855 ) — Deemed dividend on beneficial conversion feature of MT Preferred Stock — (46,000 ) — Net loss attributable to common stockholders $ (14,308,383 ) $ (27,608,680 ) $ (35,726,669 ) Loss per common share (basic and diluted): Continuing operations $ (0.05 ) $ (0.15 ) $ (0.20 ) Discontinued operations $ (0.04 ) $ (0.03 ) $ (0.04 ) Attributable to common stockholders $ (0.09 ) $ (0.18 ) $ (0.24 ) Weighted average shares outstanding (basic and diluted) 155,422,384 151,180,222 148,748,396

Note 7 - Accounts and Other R38

Note 7 - Accounts and Other Receivables and Concentrations of Credit Risk (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	2016 2015 Trade $ 18,420 $ — Other 184,596 10,439 Total $ 203,016 $ 10,439

Note 8 - Inventory (Tables)

Note 8 - Inventory (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Inventory, Current [Table Text Block]	2016 2015 Materials $ 94,500 $ — Work-in-process 1,708 14,436 Finished goods — — Reserves — (14,436 ) Total $ 96,208 $ —

Note 9 - Property and Equipme40

Note 9 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Property, Plant and Equipment [Table Text Block]	Useful Life (in years) 2016 2015 Production machinery and equipment 5 $ 810,996 $ 1,075,216 Other machinery and equipment, primarily computers and research equipment 3 – 5 407,201 421,318 Furniture and fixtures 7 645,922 648,131 Software 3 470,669 476,530 Leasehold improvements* Term of Lease 897,584 897,584 Total $ 3,232,372 $ 3,518,779

Note 12 - Accounts Payable, A41

Note 12 - Accounts Payable, Accrued Liabilities and Other (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	2016 2015 Interest $ 5,756,519 $ 478 Contracted services 1,194,678 1,636,167 Compensation 624,345 440,879 Royalties 663 275 Other 281,651 101,549 Total $ 7,857,856 $ 2,179,348

Note 16 - Equity Instruments (T

Note 16 - Equity Instruments (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Exercise Price Number of Warrants Expiration Date Series BB $ 2.00 300,000 July 2018 Series HH 2.49 301,205 June 2023 Series II 3.04 275,000 June 2018 Series KK 1.918 391,032 March 2021 Series LL 0.01 9,777,130 August 2035 Series MM 2.50 150,000 September 2019 Series MM 2.50 150,000 October 2019 Total $ 0.33 * 11,344,367

Note 18 - Income Taxes (Tables)

Note 18 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	As of December 31, 2016 2015 Deferred tax assets: Net operating loss carryforwards $ 66,150,646 $ 60,129,827 R&D credit carryforwards 9,729,673 9,465,900 Stock compensation 1,368,458 1,898,394 Intangibles 1,720,761 1,921,934 Temporary differences 132,476 801,002 Deferred tax assets before valuation allowance 79,102,014 74,217,057 Valuation allowance (79,102,014 ) (74,217,057 ) Net deferred tax assets $ — $ —
Summary of Tax Credit Carryforwards [Table Text Block]	As of December 31, 2016 Generated Expiration U.S. Net Operating Loss Carryforwards U.S. R&D Credit Carryforwards 1998 2018 $ 17,142,781 $ 1,173,387 1999 2019 — 130,359 2000 2020 — 71,713 2001 2021 — 39,128 2002 2022 1,282,447 5,350 2003 2023 337,714 2,905 2004 2024 1,237,146 22,861 2005 2025 2,999,083 218,332 2006 2026 3,049,735 365,541 2007 2027 2,842,078 342,898 2008 2028 2,777,503 531,539 2009 2029 13,727,950 596,843 2010 2030 5,397,680 1,094,449 2011 2031 1,875,665 1,950,744 2012 2032 28,406,659 468,008 2013 2033 37,450,522 681,772 2014 2034 34,088,874 816,116 2015 2035 25,073,846 492,732 2016 2036 15,581,209 358,404 Total carryforwards $ 193,270,891 $ 9,363,081
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Years Ended December 31, 2016 2015 2014 Amount % Amount % Amount % Benefit at statutory rate $ (2,508,264 ) (34.0 )% $ (7,835,163 ) (34.0 )% $ (10,322,016 ) (34.0 )% Adjustments to valuation allowance 2,354,656 31.9 % 8,212,163 35.7 % 11,046,650 36.4 % Adjustments to R&D credit carryforwards (239,049 ) (3.2 )% (612,087 ) (2.7 )% (340,886 ) (1.1 )% Disqualified debt interest 188,060 2.5 % 438,007 1.9 % — 0.0 % Permanent items and other 204,597 2.8 % (202,920 ) (0.9 )% (383,748 ) (1.3 )% Benefit per financial statements $ — $ — $ —

Note 19 - Segments (Tables)

Note 19 - Segments (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Year Ended December 31, 2016 Diagnostics Therapeutics Corporate Total Tc99m tilmanocept sales revenue: United States $ — $ — $ — $ — International 39,601 — — 39,601 Tc99m tilmanocept license revenue 1,795,625 — — 1,795,625 Grant and other revenue 3,011,642 124,766 — 3,136,408 Total revenue 4,846,868 124,766 — 4,971,634 Cost of goods sold, excluding depreciation and amortization 62,260 — — 62,260 Research and development expenses, excluding depreciation and amortization 6,375,929 762,151 — 7,138,080 Selling, general and administrative expenses, excluding depreciation and amortization ( a ) — 63,158 7,403,329 7,466,487 Depreciation and amortization ( b ) 56,317 — 397,232 453,549 Income (loss) from operations ( c ) (1,647,638 ) (700,543 ) (7,800,561 ) (10,148,742 ) Other income (expense), excluding equity in the loss of R-NAV, LLC ( d ) — — 2,786,007 2,786,007 Equity in the loss of R-NAV, LLC — — (15,159 ) (15,159 ) Net loss from continuing operations (1,647,638 ) (700,543 ) (5,029,713 ) (7,377,894 ) Loss from discontinued operations, net of tax effect (6,931,137 ) — — (6,931,137 ) Net income (loss) (8,578,775 ) (700,543 ) (5,029,713 ) (14,309,031 ) Total assets, net of depreciation and amortization: United States $ 3,815,271 $ 15,075 $ 8,498,797 $ 12,329,143 International 131,752 — 781 132,533 Capital expenditures — — 1,847 1,847 Year Ended December 31, 2015 Diagnostics Therapeutics Corporate Total Tc99m tilmanocept sales revenue: United States $ — $ — $ — $ — International 19,075 — — 19,075 Tc99m tilmanocept license revenue 1,133,333 — — 1,133,333 Grant and other revenue 1,860,953 — — 1,860,953 Total revenue 3,013,361 — — 3,013,361 Cost of goods sold, excluding depreciation and amortization 3,226 — — 3,226 Research and development expenses, excluding depreciation and amortization 9,831,834 730,895 — 10,562,729 Selling, general and administrative expenses, excluding depreciation and amortization ( a ) — 123,884 10,242,066 10,365,950 Depreciation and amortization (b ) 232,091 — 290,105 522,196 Loss from operations ( c ) (7,053,790 ) (854,779 ) (10,532,171 ) (18,440,740 ) Other income (expense), excluding equity in the loss of R-NAV, LLC ( d ) — — (4,298,604 ) (4,298,604 ) Equity in the loss of R-NAV, LLC — — (305,253 ) (305,253 ) Net loss from continuing operations (7,053,790 ) (854,779 ) (15,136,028 ) (23,044,597 ) Income from discontinued operations, net of tax effect ( e ) (5,713,598 ) — 1,194,660 (4,518,938 ) Net loss (12,767,388 ) (854,779 ) (13,941,368 ) (27,563,535 ) Total assets, net of depreciation and amortization: United States $ 4,161,029 $ — $ 10,391,805 $ 14,552,834 International 410,666 — 1,013 411,679 Capital expenditures 26,589 — 12,412 39,001

Note 21 - Leases (Tables)

Note 21 - Leases (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Operating Leases 2017 $ 277,946 2018 284,246 2019 290,734 2020 297,405 2021 304,201 Thereafter 253,339 Total $ 1,707,871

Note 24 - Selected Quarterly 46

Note 24 - Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Quarterly Financial Information [Table Text Block]	For the Quarter Ending March 31 June 30 September 30 December 31 2016: Tc99m tilmanocept sales revenue $ 9 $ 4 $ 18 $ 9 Tc99m tilmanocept license revenue 254 246 1,296 — Grant and other revenue 686 917 511 1,022 Gross profit 947 1,166 1,821 975 Operating expenses 4,705 3,407 2,731 4,215 Loss from operations (3,758 ) (2,241 ) (910 ) (3,240 ) Loss from continuing operations (2,682 ) (817 ) (1,761 ) (2,118 ) Gain (l oss) from discontinued operations, net of tax (1,004 ) (5,865 ) 1,702 (1,764 ) Net loss attributable to common stockholders (3,686 ) (6,681 ) (59 ) (3,882 ) Loss per common share (basic and diluted) (1) Continuing operations $ (0.02 ) $ 0.00 $ (0.01 ) $ (0.01 ) Discontinued operations $ 0.00 $ (0.04 ) $ 0.01 $ (0.01 ) Attributable to common stockholders $ (0.02 ) $ (0.04 ) $ (0.00 ) $ (0.02 ) 2015: Tc99m tilmanocept sales revenue $ 4 $ — $ 9 $ 6 Tc99m tilmanocept license revenue 83 250 550 250 Grant and other revenue 190 654 477 540 Gross profit 276 904 1,034 796 Operating expenses 6,900 4,348 5,947 4,256 Loss from operations (6,623 ) (3,443 ) (4,912 ) (3,463 ) Loss from continuing operations (5,983 ) (8,171 ) (6,509 ) (1,946 ) Loss from discontinued operations, net of tax (1,309 ) (1,520 ) (1,562 ) (564 ) Net loss attributable to common stockholders (7,337 ) (9,691 ) (8,071 ) (2,510 ) Loss per common share (basic and diluted) (1) Continuing operations $ (0.04 ) $ (0.05 ) $ (0.04 ) $ (0.02 ) Discontinued operations $ (0.01 ) $ (0.01 ) $ (0.01 ) $ 0.00 Attributable to common stockholders $ (0.05 ) $ (0.06 ) $ (0.05 ) $ (0.02 )

Note 1 - Organization and Sum47

Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)	1 Months Ended		12 Months Ended			77 Months Ended
	Sep. 30, 2016USD ($)$ / sharesshares	Mar. 31, 2015USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2017USD ($)	Aug. 31, 2011USD ($)
Derivative Liability		$ 63,000	$ 63,000	$ 63,000
Impairment of Long-Lived Assets to be Disposed of			$ 0	$ 0	$ 0
Nonsoftware License Arrangement [Member] | SpePharm AG [Member]
Deferred Revenue, Additions		$ 2,000,000
Deferred Revenue, Recognition Period		2 years
Deferred Revenue, Revenue Recognized	$ 417,000
Lymphoseek [Member] | Cardinal Health 414 [Member]
Sales Revenue, Percent of Sales Made to Entity			99.00%	99.00%
Series NN Warrants [Member]
Share-based Compensation Arrangement By Share-based Payment Award Award, Vesting, Threshold Consecutive Trading Days	5
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life			5 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life			15 years
The 2002 and 2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			10 years
The 2002 and 2014 Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			1 year
The 2002 and 2014 Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			4 years
The 2016 Plan [Member] | Employee Stock Option [Member] | Scenario, Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | shares	10,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	100.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares	$ 2.50
PPCO [Member] | Platinum Loan Agreement [Member] | Fair Value, Inputs, Level 3 [Member]
Embedded Derivative, Fair Value of Embedded Derivative Liability			$ 153,000	$ 3,000,000
Former Executive [Member]
Accounts Payable, Disputed			894,000
Chief Executive Officer [Member] | Employee Stock Option [Member] | Scenario, Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures | shares	5,000,000
GDS Business [Member
Disposal Group, Including Discontinued Operation, Consideration							$ 30,300,000
Maximum Royalty Income						$ 20,000,000
Royalty Revenue, Net			$ 0	759,000	$ 0
Royalty Revenue, Gross				1,200,000
Royalty Revenue, Tax Effect Allocated to Discontinued Operations				$ 436,000

Note 1 - Organization and Sum48

Note 1 - Organization and Summary of Significant Accounting Policies - Assumptions Used to Calculate Fair Value of Stock Option Awards Granted (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Expected volatility	59.00%	61.00%	61.00%
Expected volatility	75.00%	64.00%	67.00%
Weighted-average volatility	60.00%	62.00%	65.00%
Expected dividends
Risk-free rate	1.20%	1.50%	1.60%
Risk-free rate	1.80%	1.90%	2.00%
Minimum [Member]
Expected term (Year)	5 years	5 years 36 days	5 years 109 days
Maximum [Member]
Expected term (Year)	6 years	6 years 109 days	7 years 146 days

Note 2 - Liquidity (Details Tex

Note 2 - Liquidity (Details Textual) - USD ($)	Mar. 03, 2017	Feb. 28, 2017	Jun. 22, 2016	Dec. 31, 2016	Jul. 01, 2016	Dec. 31, 2015	May 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash				$ 1,539,325		$ 7,166,260		$ 5,479,006	$ 32,939,026
CRG Loan Agreement, Ohio Case [Member]
Release of Cash Held in Escrow	$ 2,000,000
CRG Loan Agreement, Texas Case [Member]
Release of Cash Held in Escrow	3,000,000
Subsequent Event [Member]
Cash	15,600,000
Payables	3,700,000
Subsequent Event [Member] | CRG Loan Agreement, Ohio Case [Member]
Release of Cash Held in Escrow	2,000,000
Subsequent Event [Member] | CRG Loan Agreement, Texas Case [Member]
Release of Cash Held in Escrow	3,000,000
Term Loan Agreement [Member] | Cardinal Health 414 [Member]
Letters of Credit Outstanding, Amount	7,000,000
Term Loan Agreement [Member] | CRG [Member]
Letters of Credit Outstanding, Amount	12,000,000
Term Loan Agreement [Member] | Subsequent Event [Member] | Cardinal Health 414 [Member]
Letters of Credit Outstanding, Amount	7,000,000
Term Loan Agreement [Member] | Subsequent Event [Member] | CRG [Member]
Letters of Credit Outstanding, Amount	12,000,000
Debt Instrument, Final Payoff Amount, Threshold Above Which the Reporting Entity Will First Pay Without Resorting to Letter of Credit	59,000,000
CRG [Member] | Term Loan Agreement [Member]
Debt Instrument, Interest Rate, Stated Percentage							14.00%
Primary Bank Account Cash Taken Possession Of By Creditor			$ 4,100,000
Debt Instrument, Final Payoff Amount, Threshold Above Which the Reporting Entity Will First Pay Without Resorting to Letter of Credit	59,000,000
Debt Instrument, Amount That May Become Due Depending on the Outcome of Litigation				$ 7,000,000
CRG [Member] | Term Loan Agreement [Member] | Maximum [Member]
Debt Instrument, Agreed-upon Final Payoff Amount	66,000,000
CRG [Member] | Term Loan Agreement [Member] | Subsequent Event [Member]
Minimum Liquidity Requirement		$ 5,000,000
Annual Revenue Target		$ 22,500,000
Debt Instrument, Interest Rate, Stated Percentage		14.00%
Debt Instrument, Default, Interest Rate, Stated Percentage		18.00%
Repayments of Debt	59,000,000
Debt Instrument, Final Payoff Amount, Threshold Above Which the Reporting Entity Will First Pay Without Resorting to Letter of Credit	59,000,000
CRG [Member] | Term Loan Agreement [Member] | Subsequent Event [Member] | Minimum [Member]
Debt Instrument, Agreed-upon Final Payoff Amount	47,000,000
CRG [Member] | Term Loan Agreement [Member] | Subsequent Event [Member] | Maximum [Member]
Debt Instrument, Agreed-upon Final Payoff Amount	66,000,000
PPCO [Member] | Platinum Loan Agreement [Member]
Debt Instrument, Interest Rate, Stated Percentage					8.125%
Repayments of Debt	7,700,000
Convertible Debt	1,900,000
PPCO [Member] | Platinum Loan Agreement [Member] | Subsequent Event [Member]
Repayments of Debt	7,700,000
Convertible Debt	$ 1,900,000

Note 3 - Discontinued Operati50

Note 3 - Discontinued Operations (Details Textual) - USD ($)	Mar. 03, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax		$ (1,764,000)	$ 1,702,000	$ (5,865,000)	$ (1,004,000)	$ (564,000)	$ (1,562,000)	$ (1,520,000)	$ (1,309,000)	$ (6,931,137)	$ (4,518,938)	[1]	$ (5,367,801)
Disposa Group, Including Discontinued Operation, Royalty Revenue											1,194,660
GDS Business [Member
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax											759,000
Disposa Group, Including Discontinued Operation, Royalty Revenue											1,200,000
Discontinued Operation, Tax Effect of Income (Loss) from Discontinued Operation During Phase-out Period											$ 436,000
Sale of Assets to Cardinal Health 414 [Member] | Subsequent Event [Member]
Sale of Assets, Cash Received from Buyer, After Adjustments, Inventory Transferred	$ 80,600,000
Sale of Assets, Cash Received from Buyer, After Adjustments, Advances of Guaranteed Earnout Payments	$ 3,000,000
[1]	Amount not allocated to a reportable segment represents contingent consideration recognized related to 2015 GDS Business revenue royalties pursuant to the 2011 sale of the GDS Business to Devicor, net of tax effect. See Note 1(a).

Note 3 - Discontinued Operati51

Note 3 - Discontinued Operations - Discontinued Operations (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net	$ 1,598,994	$ 3,692,747
Disposal Group, Including Discontinued Operation, Inventory	1,374,618	652,906
Prepaid expenses	170,635	172,585
Assets associated with discontinued operations, current	3,144,247	4,518,238
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent	70,973	151,412
Patents and trademarks, net of accumulated amortization	34,282	39,473
Assets associated with discontinued operations, noncurrent	105,255	190,885
Total assets associated with discontinued operations	3,249,502	4,709,123
Disposal Group, Including Discontinued Operation, Accounts Payable, Current	1,957,938	242,220
Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current	607,659	859,365
Deferred revenue	2,300,000
Liabilities associated with discontinued operations, current	4,865,597	1,101,585
Other liabilities		1,000,000
Total liabilities associated with discontinued operations	4,865,597	2,101,585
Lymphoseek sales revenue	16,997,497	10,235,277	$ 4,220,753
Disposa Group, Including Discontinued Operation, Royalty Revenue		1,194,660
Grant and other revenue	575	669
Total revenue	16,998,072	11,430,606	4,220,753
Cost of goods sold	2,234,780	1,751,537	1,583,519
Gross profit	14,763,292	9,679,069	2,637,234
Research and development	1,744,496	2,225,004	1,662,611
Selling, general and administrative	5,093,529	6,369,183	6,016,087
Total operating expenses	6,838,025	8,594,187	7,678,698
Income (loss) from discontinued operations	7,925,267	1,084,882	(5,041,464)
Interest expense	(14,856,404)	(5,603,820)	(326,337)
Loss from discontinued operations	$ (6,931,137)	$ (4,518,938)	$ (5,367,801)

Note 4 - Fair Value (Details Te

Note 4 - Fair Value (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2015
Derivative Liability	$ 63,000	$ 63,000		$ 63,000
Fair Value, Inputs, Level 1 [Member]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)	(2,900,000)	615,000	$ 1,300,000
Fair Value, Inputs, Level 2 [Member]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	0	0
PPCO [Member] | Platinum Loan Agreement [Member]
Convertible Debt, Fair Value Disclosures	$ 153,000	$ 3,000,000

Note 4 - Fair Value - Financial

Note 4 - Fair Value - Financial Liabilities Measured At Fair Value On a Recurring Basis (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2015
Derivative Liability	$ 63,000	$ 63,000	$ 63,000
PPCO [Member] | Platinum Loan Agreement [Member]
Convertible Debt, Fair Value Disclosures	153,000	3,000,000
Fair Value, Measurements, Recurring [Member]
Derivative Liability	63,000	63,000
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Derivative Liability
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Derivative Liability
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Derivative Liability	63,000	63,000
Fair Value, Measurements, Recurring [Member] | PPCO [Member] | Platinum Loan Agreement [Member]
Convertible Debt, Fair Value Disclosures	153,357	3,011,880
Fair Value, Measurements, Recurring [Member] | PPCO [Member] | Fair Value, Inputs, Level 1 [Member] | Platinum Loan Agreement [Member]
Convertible Debt, Fair Value Disclosures
Fair Value, Measurements, Recurring [Member] | PPCO [Member] | Fair Value, Inputs, Level 2 [Member] | Platinum Loan Agreement [Member]
Convertible Debt, Fair Value Disclosures
Fair Value, Measurements, Recurring [Member] | PPCO [Member] | Fair Value, Inputs, Level 3 [Member] | Platinum Loan Agreement [Member]
Convertible Debt, Fair Value Disclosures	$ 153,357	$ 3,011,880

Note 4 - Fair Value - Assumptio

Note 4 - Fair Value - Assumptions Used (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Estimated volatility	76.00%	58.00%
Expected term (Year)	4 years 273 days	5 years 273 days
Debt rate	8.125%	14.125%
Beginning stock price (in dollars per share)	$ 0.64	$ 1.33

Note 5 - Stock-based Compensa55

Note 5 - Stock-based Compensation (Details Textual) - USD ($)	1 Months Ended								12 Months Ended
	Feb. 28, 2016	Jul. 31, 2015	May 31, 2015	Apr. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	May 31, 2014	Mar. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Allocated Share-based Compensation Expense									$ 224,000	$ 2,400,000	$ 1,600,000
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense									$ 0	$ 0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value									$ 0.53	$ 1.67	$ 1.56
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period									50,000	146,625	468,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value									$ 23,000	$ 144,000	$ 582,000
Stock Issued During Period, Shares, Share-based Compensation, Gross									50,000	124,238	299,360
Proceeds from Stock Options Exercised									$ 13,500	$ 66,000	$ 70,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value									3,000	277,000	4,000
Payments Related to Tax Withholding for Share-based Compensation									0	$ 23,906	$ 130,537
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized									$ 223,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition									1 year 73 days
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period								100,000	66,000	333,250	216,250
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value								$ 205,000	$ 63,000	$ 511,000	$ 387,000
Restricted Stock [Member] | Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period				20,000							40,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value				$ 32,000							$ 52,000
Stock Issued During Period, Shares, Share-based Compensation, Forfeited	100,000		20,000
Stock Issued During Period, Value, Share-based Compensation, Forfeited	$ 96,000		$ 25,000
Restricted Stock [Member] | Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period									66,000	120,000	61,250
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value									$ 63,000	$ 193,000	$ 111,000
Stock Issued During Period, Shares, Share-based Compensation, Forfeited		61,000							106,000
Stock Issued During Period, Value, Share-based Compensation, Forfeited		$ 107,000							$ 118,000
Restricted Stock [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period										193,250
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value										$ 286,000
Stock Issued During Period, Shares, Share-based Compensation, Forfeited										27,000
Stock Issued During Period, Value, Share-based Compensation, Forfeited										$ 50,000
Restricted Stock [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period					15,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value					$ 19,000
Stock Issued During Period, Shares, Share-based Compensation, Forfeited						125,000	175,000
Stock Issued During Period, Value, Share-based Compensation, Forfeited						$ 166,000	$ 278,000

Note 5 - Stock-based Compensa56

Note 5 - Stock-based Compensation - Summary of Stock Option Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Outstanding at beginning of year (in shares)	5,437,064
Outstanding at beginning of period, weighted average exercise price (in dollars per share)	$ 1.96
Granted (in shares)	479,457
Granted, weighted average exercise price (in dollars per share)	$ 1.05
Exercised (in shares)	(50,000)	(146,625)	(468,000)
Exercised, weighted average exercise price (in dollars per share)	$ 0.27
Canceled and forfeited (in shares)	(2,186,906)
Canceled and Forfeited, weighted average exercise price (in dollars per share)	$ 1.69
Expired (in shares)	(299,000)
Expired, weighted average exercise price (in dollars per share)	$ 2.42
Outstanding at end of year (in shares)	3,380,615	5,437,064
Outstanding at end of period, weighted average exercise price (in dollars per share)	$ 2	$ 1.96
Outstanding at end of period, weighted average remaining contractual life (Year)	6 years 182 days
Outstanding at end of year	$ 16,013
Exercisable at end of year (in shares)	2,548,681
Exercisable at end of period, weighted average exercise price (in dollars per share)	$ 2.07
Exercisable at end of period, weighted average remaining contractual life (Year)	6 years 36 days
Exercisable at end of year	$ 16,013

Note 5 - Stock-based Compensa57

Note 5 - Stock-based Compensation - Summary of Unvested Restricted Stock (Details) - Restricted Stock [Member] - $ / shares	1 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Unvested at beginning of year (in shares)		361,000
Unvested at beginning of year (in dollars per share)		$ 1.69
Granted (in shares)		168,000
Granted, weighted average grant-date fair value (in dollars per share)		$ 1.20
Forfeited (in shares)		(206,000)
Forfeited, weighted average grant-date fair value (in dollars per share)		$ 1.77
Expired (in shares)		(50,000)
Expired (in shares)		1.93
Vested (in shares)	(100,000)	(66,000)	(333,250)	(216,250)
Vested, weighted average grant-date fair value (in dollars per share)		$ 1.65
Unvested at end of year (in shares)		207,000	361,000
Unvested at end of year (in dollars per share)		$ 1.17	$ 1.69

Note 6 - Earnings Per Share (De

Note 6 - Earnings Per Share (Details Textual) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Stock Options, Warrants, Convertible Debt, and Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	14,100,000	14,600,000	19,000,000
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	207,000	361,000	498,250

Note 6 - Earnings Per Share - C

Note 6 - Earnings Per Share - Calculation of Basic and Diluted (Loss) Per Share (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Net loss									$ (14,309,031)	$ (27,563,535)	$ (35,726,669)
Less loss attributable to noncontrolling interest									(648)	(855)
Deemed dividend on beneficial conversion feature of MT Preferred Stock										(46,000)
Net loss attributable to common stockholders	$ (3,882,000)	$ (59,000)	$ (6,681,000)	$ (3,686,000)	$ (2,510,000)	$ (8,071,000)	$ (9,691,000)	$ (7,337,000)	$ (14,308,383)	$ (27,608,680)	$ (35,726,669)
us-gaap_EarningsPerShareAbstract
Continuing operations (in dollars per share)									$ (0.05)	$ (0.15)	$ (0.20)
Discontinued operations (in dollars per share)									(0.04)	(0.03)	(0.04)
Attributable to common stockholders (in dollars per share)									$ (0.09)	$ (0.18)	$ (0.24)
Weighted average shares outstanding (basic and diluted) (in shares)									155,422,384	151,180,222	148,748,396

Note 7 - Accounts and Other R60

Note 7 - Accounts and Other Receivables and Concentrations of Credit Risk (Details Textual) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Allowance for Doubtful Accounts Receivable, Current	$ 0	$ 0
Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net	$ 1,598,994	$ 3,692,747

Note 7 - Accounts and Other R61

Note 7 - Accounts and Other Receivables and Concentrations of Credit Risk - Accounts and Other Receivables (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Trade	$ 203,016	$ 10,439
Trade Accounts Receivable [Member]
Trade	18,420
Other Accounts Receivable [Member]
Trade	$ 184,596	$ 10,439

Note 8 - Inventory (Details Tex

Note 8 - Inventory (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Inventory Valuation Reserves	$ 0	$ 14,436
Increase (Decrease) in Inventories	861,274	(135,986)	$ (761,024)
Disposal Group, Including Discontinued Operation, Inventory	1,374,618	652,906
TC 99 M Tilmanocept [Member]
Increase (Decrease) in Inventories	(131,000)	(446,000)
Inventory Write-down	43,000	52,000
Production [Member]
Inventory Write-down	$ 0	$ 120,000

Note 8 - Inventory - Components

Note 8 - Inventory - Components of Inventory (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Materials	$ 94,500
Work-in-process	1,708	14,436
Finished goods
Reserves	0	(14,436)
Total	$ 96,208

Note 9 - Property and Equipme64

Note 9 - Property and Equipment (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment, Gross	$ 3,232,372	$ 3,518,779
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	2,051,787	1,742,583
Depreciation, Depletion and Amortization	496,178	562,468	$ 487,906
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent	70,973	151,412
Assets Held under Capital Leases [Member]
Property, Plant and Equipment, Gross	$ 0	9,000
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment		$ 7,000

Note 9 - Property and Equipme65

Note 9 - Property and Equipment - Summary of Major Classes of Property and Equipment (Details) - USD ($)		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment, Gross		$ 3,232,372	$ 3,518,779
Machinery and Equipment [Member]
Property and Equipment, Useful Life (Year)		5 years
Property, Plant and Equipment, Gross		$ 810,996	1,075,216
Other Machinery and Equipment [Member]
Property, Plant and Equipment, Gross		$ 407,201	421,318
Other Machinery and Equipment [Member] | Minimum [Member]
Property and Equipment, Useful Life (Year)		3 years
Other Machinery and Equipment [Member] | Maximum [Member]
Property and Equipment, Useful Life (Year)		5 years
Furniture and Fixtures [Member]
Property and Equipment, Useful Life (Year)		7 years
Property, Plant and Equipment, Gross		$ 645,922	648,131
Purchased Software [Member]
Property and Equipment, Useful Life (Year)		3 years
Property, Plant and Equipment, Gross		$ 470,669	476,530
Leasehold Improvements [Member]
Property, Plant and Equipment, Gross	[1]	$ 897,584	$ 897,584
Property and Equipment, Useful Life	[1]	Term of Lease
Leasehold Improvements [Member] | Minimum [Member]
Property and Equipment, Useful Life	[1]	Term of Lease
Leasehold Improvements [Member] | Maximum [Member]
Property and Equipment, Useful Life	[1]	Term of Lease
[1]	* We amortize leasehold improvements over the term of the lease, which in all cases is shorter than the estimated useful life of the asset.

Note 10 - Investment in Macro66

Note 10 - Investment in Macrophage Therapeutics, Inc. (Details Textual) - USD ($)	Mar. 11, 2015	Mar. 31, 2015	May 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Preferred Stock, Shares Authorized				5,000,000	5,000,000
Preferred Stock, Par or Stated Value Per Share				$ 0.001	$ 0.001
Preferred Stock, Shares Issued				0	0
Derivative Liability		$ 63,000		$ 63,000	$ 63,000
Preferred Stock Dividends and Other Adjustments					46,000
Preferred Convertible Stock, Right to Exchange for Common Shares, Minimum Required Proceeds from Initial Public Offering					$ 50,000,000
Weighted Average Price Common Stock Percentage					80.00%
Future Common Stock Conversion Share Price					3.00%
Dr. Michael Goldberg [Member]
Convertible Preferred Stock, Percent of Shares Reserved		40.00%
Dr. Michael Goldberg [Member] | MT [Member]
Payments to Acquire Businesses and Interest in Affiliates		$ 200,000
Macrophage Therapeutics [Member]
Common Stock Shares Authorized Upon Exercise of Warrants		1,500
Convertible Preferred Stock Shares Issued Upon Conversion, Per Unit		1
Common Stock Warrants, Issued Upon Conversion, Per Unit		30
Macrophage Therapeutics [Member] | Common Stock [Member]
Common Stock as Percentage of Common Equity		1.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	300			300
Platinum [Member] | MT [Member]
Payments to Acquire Businesses and Interest in Affiliates		$ 300,000	$ 200,000
MT [Member]
Convertible Preferred Stock, PIK Coupon, Percentage			10.00%
Convertible Preferred Stock, Conversion Price, Market Cap			$ 500,000,000
Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized		50
Preferred Stock, Par or Stated Value Per Share		$ 50,000
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants	$ 500,000
Issuance of Stock and Warrants for Purchase Agreement, Remaining Amount					$ 2,000,000
Preferred Stock, Fair Value Put Option					113,000
Future Common Stock Conversion Denominator, Value					50,000
Convertible Preferred Stock [Member] | Macrophage Therapeutics [Member]
Preferred Stock, Shares Authorized		50
Preferred Stock, Shares Issued		10
Preferred Stock Dividends and Other Adjustments		$ 46,000			$ 46,000
Preferred Stock, Redemption Price Per Share					$ 58,320

Note 11 - Investment in R-NAV67

Note 11 - Investment in R-NAV, LLC (Details Textual) - USD ($)	May 31, 2016	Jul. 15, 2014	Jul. 31, 2016	Jul. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Payments to Acquire Equity Method Investments							$ 333,334
Repayments of Notes Payable					231,453	30,333,333	25,000,000
Equity Method Investment, Payment Upon Termination of Joint Venture					110,000
Equity Method Investment, Realized Gain (Loss) on Disposal					(39,732)
Income (Loss) from Equity Method Investments					(15,159)	$ (305,253)	(523,809)
R-NAV [Member]
Equity Method Investment, Initial Capitalization		$ 4,000,000
Payments to Acquire Equity Method Investments		333,334
Equity Method Investment, Promissory Note Payable		$ 666,666					666,666
Repayments of Notes Payable			$ 333,333	$ 333,333
Equity Method Investment, Ownership Shares Contingently Receivable		500,000
Equity Method Investment, Ownership Percentage		33.70%				27.30%
Equity Method Investment, Payment Upon Termination of Joint Venture	$ 110,000		110,000
Equity Method Investment, Forgiven Promissory Note, Amount	333,333		$ 333,333
Equity Method Investment, Realized Gain (Loss) on Disposal					39,732
Equity Method Investment, Aggregate Cost		$ 1,000,000
Equity Method Investments	0	$ 727,000
Income (Loss) from Equity Method Investments					15,159	$ 305,253	523,809
Equity Method Investment, Commitment to Provide Services					500,000
Equity Method Investment, Cost of Services Provided					$ 15,000	64,000	$ 39,000
Equity Method Investment, Remaining Commitment to Provide Services	$ 383,000
R-NAV [Member] | Common Stock [Member]
Equity Method Investment, Ownership Shares Received		3,500,000
Equity Method Investment, Shares Transferred Upon Termination of Joint Venture	3,500,000		3,500,000
R-NAV [Member] | Preferred Stock [Member]
Equity Method Investment, Ownership Shares Received		1,000,000
Equity Method Investment, Shares Transferred Upon Termination of Joint Venture	1,500,000		1,500,000
R-NAV [Member] | Commitment to Invest [Member]
Other Commitment		$ 1,000,000
R-NAV's Subsidiary 1A [Member] | Call Option [Member]
Warrants and Rights Outstanding						$ 10,500,000
Equity Method Investments		$ 273,000

Note 12 - Accounts Payable, A68

Note 12 - Accounts Payable, Accrued Liabilities and Other (Details Textual) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Disposal Group, Including Discontinued Operation, Accounts Payable, Current	$ 1,957,938	$ 242,220
Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current	607,659	859,365
Accounts Payable [Member] | Director Fees and Scientific Advisory Board Fees [Member]
Due to Related Parties, Current	116,000	7,000
Accrued Liabilities and Other [Member] | Executive Bonuses, Director Fees, Deferred Salary, and Scientific Advisory Board Fees [Member]
Due to Related Parties, Current	$ 106,000	$ 83,000

Note 12 - Accounts Payable, A69

Note 12 - Accounts Payable, Accrued Liabilities and Other - Accrued Liabilities and Other (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Interest Payable, Current	$ 5,756,519	$ 478
Contracted services	1,194,678	1,636,167
Compensation	624,345	440,879
Royalties	663	275
Other	281,651	101,549
Total	$ 7,857,856	$ 2,179,348

Note 13 - Notes Payable (Detail

Note 13 - Notes Payable (Details Textual)		Mar. 03, 2017USD ($)	Jul. 01, 2016	Jun. 22, 2016USD ($)	May 31, 2016USD ($)shares	Mar. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / shares	Jul. 31, 2016USD ($)shares	Jul. 31, 2015USD ($)	May 31, 2015USD ($)$ / shares	Mar. 31, 2014USD ($)$ / sharesshares	Jun. 30, 2013USD ($)$ / sharesshares	Dec. 31, 2015USD ($)	Dec. 31, 2016USD ($)$ / shares	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Jun. 25, 2013USD ($)	Feb. 28, 2017	Jul. 31, 2014USD ($)	Jul. 31, 2012USD ($)
Repayments of Notes Payable														$ 231,453	$ 30,333,333	$ 25,000,000
Change in Fair Value of Financial Instruments														2,858,524	(614,782)	(1,342,389)
Interest Payable, Current							$ 5,756,519						$ 478	$ 5,756,519	478
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	[1]						$ 0.33							$ 0.33
Debt Instrument, Unamortized Discount							$ 0						2,033,506	$ 0	2,033,506
Gain (Loss) on Extinguishment of Debt															(2,440,714)	(2,610,196)
Equity Method Investment, Payment Upon Termination of Joint Venture														110,000
Interest Expense, Debt														5,000	1,300,000	3,400,000
Interest Expense Recorded Related to Amortization of Debt Discounts and Deferred Financing Costs															326,000	844,000
Disposal Group, Including Discontinued Operation, Interest Expense														14,856,404	5,603,820	326,337
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months							52,000,000							52,000,000
Long-term Debt, Maturities, Repayments of Principal in Year Two							0							0
Long-term Debt, Maturities, Repayments of Principal in Year Three							0							0
Long-term Debt, Maturities, Repayments of Principal in Year Four							0							0
Long-term Debt, Maturities, Repayments of Principal in Year Five							9,500,000							9,500,000
Long-term Debt, Maturities, Repayments of Principal after Year Five							$ 0							$ 0
R-NAV [Member]
Repayments of Notes Payable								$ 333,333	$ 333,333
Debt Instrument, Face Amount																				$ 666,666
Equity Method Investment, Payment Upon Termination of Joint Venture					$ 110,000			110,000
Equity Method Investment, Forgiven Promissory Note, Amount					$ 333,333			$ 333,333
R-NAV [Member] | Preferred Stock [Member]
Equity Method Investment, Shares Transferred Upon Termination of Joint Venture | shares					1,500,000			1,500,000
R-NAV [Member] | Common Stock [Member]
Equity Method Investment, Shares Transferred Upon Termination of Joint Venture | shares					3,500,000			3,500,000
Series KK Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares						$ 1.918	$ 1.918				$ 1.918			$ 1.918
Series HH Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares							2.49							2.49
CRG Loan Agreement, Ohio Case [Member]
Release of Cash Held in Escrow		$ 2,000,000
CRG Loan Agreement, Texas Case [Member]
Release of Cash Held in Escrow		3,000,000
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares							0.01							0.01
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares							$ 3.04							$ 3.04
Subsequent Event [Member] | CRG Loan Agreement, Ohio Case [Member]
Release of Cash Held in Escrow		2,000,000
Subsequent Event [Member] | CRG Loan Agreement, Texas Case [Member]
Release of Cash Held in Escrow		3,000,000
Federal Funds Rate [Member] | R-NAV [Member]
Debt Instrument, Interest Rate, Stated Percentage																				0.31%
Platinum-Montaur Life Sciences LLC Litigation [Member]
Line of Credit Facility, Maximum Borrowing Capacity																					$ 50,000,000
Line of Credit Facility, Current Borrowing Capacity												$ 35,000,000									35,000,000
Line of Credit Facility, Increase Additional Borrowings Terms Not Negotiated							$ 15,000,000							$ 15,000,000							15,000,000
Proceeds from Lines of Credit														0	4,500,000	0	$ 4,000,000	$ 8,000,000
Debt Instrument, Interest Rate, Stated Percentage						10.00%				10.00%	10.00%	10.00%
InterestRateInAdditionToAmendedAgreement												0.125%
Percentage of VWAP for Conversion Calculation												90.00%
Period of Preceding Date of Conversion Request												10 days
Minimum Revenue from Sales and Licensing for Mandatory Repayment Due												$ 2,000,000
Repayments of Notes Payable												$ 4,800,000
Stock for Stock Conversion Number of Shares Converted | shares												2,364.9
Number of Common Shares Underlying Series B Preferred Stock | shares												7,733,223
Shares Conversion, Number of Common Stock Equivalent to Each Preferred Stock | shares												3,270
Debt Instrument, Convertible, Threshold Trading Days										10
Debt Instrument, Convertible, Stock Price Trigger | $ / shares										$ 2.53
Embedded Derivative, Fair Value of Embedded Derivative Liability							153,000							153,000
Change in Fair Value of Financial Instruments														2,900,000	(615,000)	(1,300,000)
Convertible Debt, Fair Value Disclosures							9,600,000						11,500,000	9,600,000	11,500,000
Interest Expense, Debt, Excluding Amortization														1,000,000	761,000
Line of Credit Facility, Decrease Forgiveness Interest Percentage			6.00%
Notes Payable							9,500,000							9,500,000
Long-term Line of Credit							7,700,000							7,700,000
Interest Payable, Current							1,800,000							1,800,000
Line of Credit Facility, Remaining Borrowing Capacity							27,300,000							27,300,000
Platinum-Montaur Life Sciences LLC Litigation [Member] | Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate										6.75%	6.75%	6.75%
Platinum-Montaur Life Sciences LLC Litigation [Member] | Oxford Financing Rate [Member]
Debt Instrument, Basis Spread on Variable Rate						0.125%
Platinum-Montaur Life Sciences LLC Litigation [Member] | Interest Rate Pursuant to CRG Term Loan [Member]
Debt Instrument, Basis Spread on Variable Rate										0.125%
Platinum Loan Agreement [Member] | PPCO [Member]
Line of Credit Facility, Maximum Borrowing Capacity																					$ 50,000,000
Debt Instrument, Interest Rate, Stated Percentage			8.125%
Convertible Debt, Fair Value Disclosures							153,000						3,000,000	153,000	3,000,000
Repayments of Debt		7,700,000
Convertible Debt		1,900,000
Platinum Loan Agreement [Member] | PPCO [Member] | Subsequent Event [Member]
Repayments of Debt		7,700,000
Convertible Debt		1,900,000
Term Loan Agreement [Member] | Cardinal Health 414 [Member]
Letters of Credit Outstanding, Amount		7,000,000
Term Loan Agreement [Member] | CRG [Member]
Letters of Credit Outstanding, Amount		12,000,000
Term Loan Agreement [Member] | Subsequent Event [Member] | Cardinal Health 414 [Member]
Letters of Credit Outstanding, Amount		7,000,000
Term Loan Agreement [Member] | Subsequent Event [Member] | CRG [Member]
Letters of Credit Outstanding, Amount		12,000,000
Debt Instrument, Final Payoff Amount, Threshold Above Which the Reporting Entity Will First Pay Without Resorting to Letter of Credit		59,000,000
Term Loan Agreement [Member] | CRG [Member]
Debt Instrument, Interest Rate, Stated Percentage										14.00%
Interest Expense, Debt, Excluding Amortization														553,000	1,300,000
Notes Payable							51,700,000						51,300,000	51,700,000	51,300,000
Debt Instrument, Face Amount										$ 50,000,000
Debt Instrument, Additional Loans That May Be Made Available Upon the Satisfaction of Certain Conditions										$ 10,000,000
Percentage of Per Annum Interest Paying in Cash										10.00%
Percentage of Per Annum Interest as Compounded Interest										4.00%
Debt Instrument, Number of Quarterly Payments										8
Debt Instrument Payment Terms Payment Period										2 years
Debt Instrument, Unamortized Discount (Premium), Net										$ 2,200,000
Debt Instrument End of Term Fee, Amount										1,000,000
Debt Instrument, Fee Amount										1,000,000
Debt Instrument, Covenant Compliance, Income (Loss) Earnings Before Interest, Taxes, Depreciation, and Amortization, Minimum										5,000,000
Debt Instrument, Covenant Compliance Sales Revenue Minimum Next Twelve Months							22,500,000							22,500,000
DebtInstrumentCovenantComplianceTargetRevenueMinimum										$ 45,000,000
Debt Instrument, Covenant Compliance Cure Right Ratio										2.5
Debt Instrument, Covenant Compliance Liquidity Minimum										$ 5,000,000
Debt Instrument, Interest Rate in the Event of Default										18.00%
Primary Bank Account Cash Taken Possession Of By Creditor				$ 4,100,000
Payments to Prepayment Premium and Backend Facility Fee on Claims of Default				3,900,000
Payments to Principal Balance of Debt on Claims of Default				$ 189,000
Debt Instrument, Final Payoff Amount, Threshold Above Which the Reporting Entity Will First Pay Without Resorting to Letter of Credit		59,000,000
Term Loan Agreement [Member] | CRG [Member] | Maximum [Member]
Debt Instrument, Agreed-upon Final Payoff Amount		66,000,000
Term Loan Agreement [Member] | CRG [Member] | Subsequent Event [Member]
Debt Instrument, Interest Rate, Stated Percentage																			14.00%
Repayments of Debt		59,000,000
Debt Instrument, Final Payoff Amount, Threshold Above Which the Reporting Entity Will First Pay Without Resorting to Letter of Credit		59,000,000
Term Loan Agreement [Member] | CRG [Member] | Subsequent Event [Member] | Minimum [Member]
Debt Instrument, Agreed-upon Final Payoff Amount		47,000,000
Term Loan Agreement [Member] | CRG [Member] | Subsequent Event [Member] | Maximum [Member]
Debt Instrument, Agreed-upon Final Payoff Amount		$ 66,000,000
Term Loan Agreement [Member] | CRG [Member] | Accrued Liabilities and Other [Member]
Interest Payable, Current							$ 5,800,000						0	$ 5,800,000	0
Oxford Finance, LLC [Member]
Debt Instrument, Interest Rate, Stated Percentage						8.50%					8.50%
Debt Instrument, Face Amount						$ 30,000,000					$ 30,000,000
Debt Instrument, Unamortized Discount (Premium), Net						3,000,000					3,000,000
Debt Instrument End of Term Fee, Amount											2,400,000		2,400,000
Repayments of Long-term Debt										$ 31,700,000
Debt Instrument, Early Redemption Fee Amount										$ 289,000
Long-term Debt, Gross													$ 0		$ 0
Oxford Finance, LLC [Member] | Series KK Warrants [Member]
Debt Instrument, Unamortized Discount (Premium), Net						$ 120,000					$ 120,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares						391,032					391,032
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares						$ 1.918					$ 1.918
GECC/MidCap Financial SBIC LP [Member]
Debt Instrument, Interest Rate, Stated Percentage												9.83%
Debt Instrument, Face Amount												$ 25,000,000
Debt Instrument End of Term Fee, Amount											$ 1,000,000	$ 1,000,000
Repayments of Long-term Debt											26,700,000
Debt Instrument, Early Redemption Fee Amount						$ 500,000					500,000
Long-term Debt, Gross																$ 0
Number of Monthly Installment Payments on Notes Payable												30
Percentage of Original Principal Amount of Loan to Be Paid as Fee												4.00%
Debt Instrument, Unamortized Discount												$ 881,000
Gain (Loss) on Extinguishment of Debt											$ 2,600,000
GECC/MidCap Financial SBIC LP [Member] | Series HH Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares												301,205
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares												$ 2.49
Debt Instrument, Unamortized Discount												$ 1,900,000
Notes Payable Issued for Prepayment of Insurance Premiums [Member] | IPFS [Member]
Debt Instrument, Interest Rate, Stated Percentage							8.99%							8.99%
Debt Instrument, Face Amount							$ 348,000							$ 348,000
Debt Instrument, Term							240 days
Debt Instrument, Periodic Payment							$ 45,000
[1]	Weighted average exercise price.

Note 14 - Commitments and Con71

Note 14 - Commitments and Contingencies (Details Textual) - USD ($)	May 16, 2017	May 12, 2017	Mar. 03, 2017	Oct. 11, 2016	Jun. 22, 2016	Feb. 28, 2017	Jul. 01, 2016	May 31, 2015
CRG Loan Agreement, Ohio Case [Member]
Release of Cash Held in Escrow			$ 2,000,000
CRG Loan Agreement, Texas Case [Member]
Release of Cash Held in Escrow			3,000,000
Former CEO Arbitration [Member]
Litigation Settlement, Salary, Bonus, and Benefits, Amount Awarded to Other Party		$ 4
Litigation Settlement, Amount Awarded to Other Party	$ 0
FTI Consulting, Inc. Litigation [Member] | Pending Litigation [Member] | Investigative and Consulting Services [Member]
Loss Contingency, Damages Sought, Value				$ 730,264
Minimum [Member] | FTI Consulting, Inc. Litigation [Member] | Pending Litigation [Member]
Loss Contingency, Damages Sought, Value				782,600
Minimum [Member] | FTI Consulting, Inc. Litigation [Member] | Pending Litigation [Member] | Purported Interest Due on Unpaid Invoices, Plus Attorneys' Fees, Costs and Expenses [Member]
Loss Contingency, Damages Sought, Value				$ 52,337
Subsequent Event [Member] | CRG Loan Agreement, Ohio Case [Member]
Release of Cash Held in Escrow			2,000,000
Subsequent Event [Member] | CRG Loan Agreement, Texas Case [Member]
Release of Cash Held in Escrow			3,000,000
Subsequent Event [Member] | Cardinal Health 414 [Member] | CRG Loan Agreement, Texas Case [Member] | Letter of Credit [Member]
Litigation Settlement, Collateral			7,000,000
Subsequent Event [Member] | CRG [Member] | CRG Loan Agreement, Texas Case [Member] | Letter of Credit [Member]
Litigation Settlement, Collateral			12,000,000
Term Loan Agreement [Member] | Cardinal Health 414 [Member]
Letters of Credit Outstanding, Amount			7,000,000
Term Loan Agreement [Member] | CRG [Member]
Letters of Credit Outstanding, Amount			12,000,000
Term Loan Agreement [Member] | Subsequent Event [Member] | Cardinal Health 414 [Member]
Letters of Credit Outstanding, Amount			7,000,000
Term Loan Agreement [Member] | Subsequent Event [Member] | CRG [Member]
Letters of Credit Outstanding, Amount			12,000,000
Debt Instrument, Final Payoff Amount, Threshold Above Which the Reporting Entity Will First Pay Without Resorting to Letter of Credit			59,000,000
PPCO [Member] | Platinum Loan Agreement [Member]
Debt Instrument, Interest Rate, Reduction in Stated Percentage							6.00%
Debt Instrument, Interest Rate, Stated Percentage							8.125%
Repayments of Debt			7,700,000
PPCO [Member] | Platinum Loan Agreement [Member] | Subsequent Event [Member]
Repayments of Debt			7,700,000
CRG [Member] | Term Loan Agreement [Member]
Debt Instrument, Interest Rate, Stated Percentage								14.00%
Primary Bank Account Cash Taken Possession Of By Creditor					$ 4,100,000
Primary Bank Account Cash Taken Possession Of By Creditor, Portion Applied to Fees					3,900,000
Primary Bank Account Cash Taken Possession Of By Creditor, Portion Applied to the Principal Balance of Debt					$ 189,000
Debt Instrument, Final Payoff Amount, Threshold Above Which the Reporting Entity Will First Pay Without Resorting to Letter of Credit			59,000,000
CRG [Member] | Term Loan Agreement [Member] | Maximum [Member]
Debt Instrument, Agreed-upon Final Payoff Amount			66,000,000
CRG [Member] | Term Loan Agreement [Member] | Subsequent Event [Member]
Debt Instrument, Interest Rate, Stated Percentage						14.00%
Repayments of Debt			59,000,000
Debt Instrument, Final Payoff Amount, Threshold Above Which the Reporting Entity Will First Pay Without Resorting to Letter of Credit			59,000,000
CRG [Member] | Term Loan Agreement [Member] | Subsequent Event [Member] | Minimum [Member]
Debt Instrument, Agreed-upon Final Payoff Amount			47,000,000
CRG [Member] | Term Loan Agreement [Member] | Subsequent Event [Member] | Maximum [Member]
Debt Instrument, Agreed-upon Final Payoff Amount			$ 66,000,000

Note 15 - Preferred Stock (Deta

Note 15 - Preferred Stock (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended			12 Months Ended		37 Months Ended
		Aug. 31, 2015	Nov. 30, 2014	Jun. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Class of Warrant or Right, Exercise Price of Warrants or Rights	[1]							$ 0.33
Preferred Stock, Shares Outstanding								0	0
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.01
Platinum Management New York LLC [Member] | Minimum [Member]
Common Stock Distribution or Issuance Effective Price		$ 1.35
Platinum [Member] | Common Stock [Member]
Conversion of Stock, Shares Issued					14,459,940	5,682,933
Platinum Partners Value Arbitrage Fund [Member] | Common Stock [Member]
Stock Repurchased During Period, Shares			4,499,520
Series LL Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.01
Series LL Warrants [Member] | Platinum Management New York LLC [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.01
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		14,777,130
Preferred Stock, Liquidation Preference, Value		$ 0
Gain (Loss) from Exchange of Warrants		$ 0
Platinum-Montaur Life Sciences LLC Litigation [Member]
Stock for Stock Conversion Number of Shares Converted				2,364.9
Number of Common Shares Underlying Series B Preferred Stock				7,733,223
Shares Conversion, Number of Common Stock Equivalent to Each Preferred Stock				3,270
Platinum-Montaur Life Sciences LLC Litigation [Member] | Series X Warrants And Series AA Warrants [Member]
Number of Common Shares Underlying Series B Preferred Stock							7,733,223
Series B Preferred Stock [Member]
Stock for Stock Conversion Number of Shares Converted							2,364.9
Preferred Stock, Shares Outstanding		0
Series B Preferred Stock [Member] | Platinum Management New York LLC [Member]
Preferred Stock Exchanged for Warrants During Period, Shares		4,519
Class of Warrant or Right, Outstanding Term		20 years
Shares Conversion, Number of Common Stock Equivalent to Each Preferred Stock		3,270
Warrant Issued Upon Exchange of Preferred Stock		14,777,130
Series B Preferred Stock [Member] | Platinum [Member]
Conversion of Stock, Shares Converted					4,422	1,737.9
Series B Preferred Stock [Member] | Platinum Partners Value Arbitrage Fund [Member]
Stock Issued During Period, Shares, New Issues			1,376
[1]	Weighted average exercise price.

Note 16 - Equity Instruments (D

Note 16 - Equity Instruments (Details Textual) - USD ($)		1 Months Ended				3 Months Ended
		Oct. 31, 2015	Oct. 30, 2015	Sep. 30, 2015	Nov. 30, 2014	Sep. 30, 2015	Dec. 31, 2016	Mar. 11, 2015	Mar. 31, 2014
Class of Warrant or Right, Outstanding							11,344,367
Class of Warrant or Right, Exercise Price of Warrants or Rights	[1]						$ 0.33
Common Stock, Capital Shares Reserved for Future Issuance							18,641,776
Series KK Warrants [Member]
Class of Warrant or Right, Outstanding							391,032		391,032
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 1.918		$ 1.918
Series JJ Warrants [Member]
Stock Issued During Period Shares Stock Warrants Exercised					3,843,223
Adjustments to Additional Paid in Capital Warrant Exercised					$ 7,700,000
Series BB [Member]
Class of Warrant or Right, Outstanding							300,000
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 2
Gains (Losses) on Extension of Warrant Expiration Date						$ 150,000
Series MM Warrants Expire September 2019 [Member]
Class of Warrant or Right, Outstanding							150,000
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 2.50
Series MM Warrants Expire September 2019 [Member] | Chardan Capital Markets, LLC [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 2.50		$ 2.50
Class of Warrant or Right, Outstanding Term				4 years
Common Stock Warrants Issued				150,000
Series MM Warrants Expire October 2019 [Member]
Class of Warrant or Right, Outstanding							150,000
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 2.50
Series MM Warrants Expire October 2019 [Member] | Chardan Capital Markets, LLC [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 2.50
Class of Warrant or Right, Outstanding Term			4 years
Common Stock Warrants Issuable			150,000
Series MM warrants [Member] | Chardan Capital Markets, LLC [Member]
Issuance of Stock and Warrants for Services or Claims						$ 256,000
Series LL Warrants [Member]
Class of Warrant or Right, Outstanding							9,777,130
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.01
Stock Issued During Period Shares Stock Warrants Exercised		4,977,679
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised		5,000,000
Common Stock [Member] | Macrophage Therapeutics [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 2,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							300	300
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.01
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 3.04
[1]	Weighted average exercise price.

Note 16 - Equity Instruments -

Note 16 - Equity Instruments - Outstanding Warrants (Details) - $ / shares		12 Months Ended
		Dec. 31, 2016	Mar. 31, 2014
Exercise Price (in dollars per share)	[1]	$ 0.33
Number of Warrants (in shares)		11,344,367
Expiration Date
Series BB [Member]
Exercise Price (in dollars per share)		$ 2
Number of Warrants (in shares)		300,000
Expiration Date		Jul. 7, 2018
Series HH Warrants [Member]
Exercise Price (in dollars per share)		$ 2.49
Number of Warrants (in shares)		301,205
Expiration Date		Jun. 25, 2023
Series II Warrants [Member]
Exercise Price (in dollars per share)		$ 3.04
Number of Warrants (in shares)		275,000
Expiration Date		Jun. 25, 2018
Series KK Warrants [Member]
Exercise Price (in dollars per share)		$ 1.918	$ 1.918
Number of Warrants (in shares)		391,032	391,032
Expiration Date		Mar. 4, 2021
Series LL Warrants [Member]
Exercise Price (in dollars per share)		$ 0.01
Number of Warrants (in shares)		9,777,130
Expiration Date		Aug. 31, 2035
Series MM Warrants Expire September 2019 [Member]
Exercise Price (in dollars per share)		$ 2.50
Number of Warrants (in shares)		150,000
Expiration Date		Sep. 30, 2019
Series MM Warrants Expire October 2019 [Member]
Exercise Price (in dollars per share)		$ 2.50
Number of Warrants (in shares)		150,000
Expiration Date		Oct. 31, 2019
[1]	Weighted average exercise price.

Note 17 - Reductions in Force (

Note 17 - Reductions in Force (Details Textual)	1 Months Ended			12 Months Ended
	Mar. 31, 2015	Jun. 30, 2014USD ($)shares	May 31, 2014USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2016USD ($)
Restructuring and Related Cost, Number of Positions Eliminated			11
Restructuring Charges				$ 1,300,000	$ 557,000
Restructuring Costs Related to Equity Awards				273,000
Restructuring Reserve				$ 9,000		$ 0
Pykett Consulting Agreement [Member]
Professional Fees		$ 27,500			94,000
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares		40,000
Montaur Services Agreement [Member]
Professional Fees			$ 15,000		$ 53,000
Chief Executive Officer [Member]
Severance Costs			$ 750,000
Staff Members [Member]
Restructuring and Related Cost, Number of Positions Eliminated	7
Executives [Member]
Restructuring and Related Cost, Number of Positions Eliminated	3

Note 18 - Income Taxes (Details

Note 18 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Deferred Tax Assets, Gross	$ 79,102,014	$ 74,217,057
Net Income (Loss) Attributable to Parent	(14,309,031)	(27,563,535)	$ (35,726,669)
Cardiosonix [Member] | Subsidiaries [Member]
Net Income (Loss) Attributable to Parent	(13,000)	(11,000)	$ (15,000)
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards	193,270,891	177,600,000
Operating LossCarryforwardsStockBasedCompensation	15,300,000	15,300,000
Net Operating Loss Carryforwards Expired in Period	0	0
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	9,363,081	9,100,000
Net Tax Credit Carryforwards Expired in Period	0	0
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	$ 28,200,000	24,700,000
State and Local Jurisdiction [Member] | Earliest Tax Year [Member]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2032
Foreign Tax Authority [Member] | Israel Tax Authority [Member] | Cardiosonix [Member] | Subsidiaries [Member]
Operating Loss Carryforwards	$ 7,700,000	$ 7,600,000

Note 18 - Income Taxes - Compon

Note 18 - Income Taxes - Components of Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
Net operating loss carryforwards	$ 66,150,646	$ 60,129,827
R&D credit carryforwards	9,729,673	9,465,900
Stock compensation	1,368,458	1,898,394
Intangibles	1,720,761	1,921,934
Temporary differences	132,476	801,002
Deferred tax assets before valuation allowance	79,102,014	74,217,057
Valuation allowance	(79,102,014)	(74,217,057)
Net deferred tax assets

Note 18 - Income Taxes - Net Op

Note 18 - Income Taxes - Net Operating Loss and Credit Carryforwards (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards	$ 193,270,891	$ 177,600,000
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 9,363,081	$ 9,100,000
Tax Year 1998 [Member]
Expiration dates	Dec. 31, 2018
Tax Year 1998 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards	$ 17,142,781
Tax Year 1998 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 1,173,387
Tax Year 1999 [Member]
Expiration dates	Dec. 31, 2019
Tax Year 1999 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards
Tax Year 1999 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 130,359
Tax Year 2000 [Member]
Expiration dates	Dec. 31, 2020
Tax Year 2000 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards
Tax Year 2000 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 71,713
Tax Year 2001 [Member]
Expiration dates	Dec. 31, 2021
Tax Year 2001 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards
Tax Year 2001 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 39,128
Tax Year 2002 [Member]
Expiration dates	Dec. 31, 2022
Tax Year 2002 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards	$ 1,282,447
Tax Year 2002 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 5,350
Tax Year 2003 [Member]
Expiration dates	Dec. 31, 2023
Tax Year 2003 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards	$ 337,714
Tax Year 2003 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 2,905
Tax Year 2004 [Member]
Expiration dates	Dec. 31, 2024
Tax Year 2004 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards	$ 1,237,146
Tax Year 2004 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 22,861
Tax Year 2005 [Member]
Expiration dates	Dec. 31, 2025
Tax Year 2005 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards	$ 2,999,083
Tax Year 2005 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 218,332
Tax Year 2006 [Member]
Expiration dates	Dec. 31, 2026
Tax Year 2006 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards	$ 3,049,735
Tax Year 2006 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 365,541
Tax Year 2007 [Member]
Expiration dates	Dec. 31, 2027
Tax Year 2007 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards	$ 2,842,078
Tax Year 2007 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 342,898
Tax Year 2008 [Member]
Expiration dates	Dec. 31, 2028
Tax Year 2008 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards	$ 2,777,503
Tax Year 2008 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 531,539
Tax Year 2009 [Member]
Expiration dates	Dec. 31, 2029
Tax Year 2009 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards	$ 13,727,950
Tax Year 2009 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 596,843
Tax Year 2010 [Member]
Expiration dates	Dec. 31, 2030
Tax Year 2010 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards	$ 5,397,680
Tax Year 2010 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 1,094,449
Tax Year 2011 [Member]
Expiration dates	Dec. 31, 2031
Tax Year 2011 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards	$ 1,875,665
Tax Year 2011 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 1,950,744
Tax Year 2012 [Member]
Expiration dates	Dec. 31, 2032
Tax Year 2012 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards	$ 28,406,659
Tax Year 2012 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 468,008
Tax Year 2013 [Member]
Expiration dates	Dec. 31, 2033
Tax Year 2013 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards	$ 37,450,522
Tax Year 2013 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 681,772
Tax Year 2014 [Member]
Expiration dates	Dec. 31, 2034
Tax Year 2014 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards	$ 34,088,874
Tax Year 2014 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 816,116
Tax Year 2015 [Member]
Expiration dates	Dec. 31, 2035
Tax Year 2015 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards	$ 25,073,846
Tax Year 2015 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 492,732
Tax Year 2016 [Member]
Expiration dates	Dec. 31, 2036
Tax Year 2016 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards	$ 15,581,209
Tax Year 2016 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 358,404

Note 18 - Income Taxes - Reconc

Note 18 - Income Taxes - Reconciliations Between the Statutory Federal Income Tax Rate and the Effective Tax Rate (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Benefit at statutory rate, amount	$ (2,508,264)	$ (7,835,163)	$ (10,322,016)
Benefit at statutory rate, percent	(34.00%)	(34.00%)	(34.00%)
Adjustments to valuation allowance, amount	$ 2,354,656	$ 8,212,163	$ 11,046,650
Adjustments to valuation allowance, percent	31.90%	35.70%	36.40%
Adjustments to R&D credit carryforwards, amount	$ (239,049)	$ (612,087)	$ (340,886)
Adjustments to R&D credit carryforwards, percent	(3.20%)	(2.70%)	(1.10%)
Disqualified debt interest, amount	$ 188,060	$ 438,007
Disqualified debt interest, percent	2.50%	1.90%	0.00%
Permanent items and other, amount	$ 204,597	$ (202,920)	$ (383,748)
Permanent items and other, percent	2.80%	(0.90%)	(1.30%)
Benefit per financial statements, amount

Note 19 - Segments (Details Tex

Note 19 - Segments (Details Textual)		12 Months Ended
		Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Revenues		$ 4,971,634	$ 3,013,361	$ 2,054,096
Number of Primary Types of Products Sold		2
Depreciation, Depletion and Amortization, Nonproduction	[1]	$ 453,549	522,196
Research and Development Expense [Member]
Depreciation, Depletion and Amortization, Nonproduction		0	10,617
Selling, General and Administrative Expenses [Member]
Depreciation, Depletion and Amortization, Nonproduction		397,232	$ 460,839
Intersegment Eliminations [Member]
Revenues		$ 0
[1]	Depreciation and amortization is reflected in research and development ($0 and $10,617 for the years ended December 31, 2016 and 2015, respectively), and selling, general and administrative expenses ($397,232 and $460,839 for the years ended December 31, 2016 and 2015, respectively).

Note 19 - Segments - Segment In

Note 19 - Segments - Segment Information (Details) - USD ($)		3 Months Ended								12 Months Ended
		Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
Tc99m tilmanocept sales revenue		$ 9,000	$ 18,000	$ 4,000	$ 9,000	$ 6,000	$ 9,000		$ 4,000	$ 39,601		$ 19,075		$ 13,200
Tc99m tilmanocept license revenue			1,296,000	246,000	254,000	250,000	550,000	250,000	83,000	1,795,625		1,133,333		300,000
Grant and other revenue		1,022,000	511,000	917,000	686,000	540,000	477,000	654,000	190,000	3,136,408		1,860,953		1,740,896
Revenues										4,971,634		3,013,361		2,054,096
Cost of goods sold, excluding depreciation and amortization										62,260		3,226
Research and Development Expense										7,138,080		10,562,729		15,116,978
Selling, general and administrative expenses, excluding depreciation and amortization	[1]									7,466,487		10,365,950
Depreciation, Depletion and Amortization, Nonproduction	[2]									453,549		522,196
Income (loss) from operations		(3,240,000)	(910,000)	(2,241,000)	(3,758,000)	(3,463,000)	(4,912,000)	(3,443,000)	(6,623,000)	(10,148,742)	[3]	(18,440,740)	[3]	(22,591,492)
Other income (expense), excluding equity in the loss of R-NAV, LLC	[4]									2,786,007		(4,298,604)
Equity in loss of R-NAV, LLC										(15,159)		(305,253)		(523,809)
Net loss from continuing operations										(7,377,894)		(23,044,597)
Loss from discontinued operations, net of tax effect		(1,764,000)	1,702,000	(5,865,000)	(1,004,000)	(564,000)	(1,562,000)	(1,520,000)	(1,309,000)	(6,931,137)		(4,518,938)	[5]	(5,367,801)
Net loss										(14,309,031)		(27,563,535)		(35,726,669)
Total assets, net of depreciation and amortization		12,461,676				14,964,513				12,461,676		14,964,513
Capital expenditures										1,847		39,001		1,114,448
Net loss from continuing operations										(7,377,894)		(23,044,597)
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax		(1,764,000)	$ 1,702,000	$ (5,865,000)	$ (1,004,000)	(564,000)	$ (1,562,000)	$ (1,520,000)	$ (1,309,000)	(6,931,137)		(4,518,938)	[5]	$ (5,367,801)
UNITED STATES
Tc99m tilmanocept sales revenue
Total assets, net of depreciation and amortization		12,329,143				14,552,834				12,329,143		14,552,834
Non-US [Member]
Tc99m tilmanocept sales revenue										39,601		19,075
Total assets, net of depreciation and amortization		132,533				411,679				132,533		411,679
Diagnostics Segment [Member]
Tc99m tilmanocept license revenue										1,795,625		1,133,333
Grant and other revenue										3,011,642		1,860,953
Revenues										4,846,868		3,013,361
Cost of goods sold, excluding depreciation and amortization										62,260		3,226
Research and Development Expense										6,375,929		9,831,834
Selling, general and administrative expenses, excluding depreciation and amortization	[1]
Depreciation, Depletion and Amortization, Nonproduction	[2]									56,317		232,091
Income (loss) from operations	[3]									(1,647,638)		(7,053,790)
Other income (expense), excluding equity in the loss of R-NAV, LLC	[4]
Equity in loss of R-NAV, LLC
Net loss from continuing operations										(1,647,638)		(7,053,790)
Loss from discontinued operations, net of tax effect										(6,931,137)		(5,713,598)	[5]
Net loss										(8,578,775)		(12,767,388)
Capital expenditures												26,589
Net loss from continuing operations										(1,647,638)		(7,053,790)
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax										(6,931,137)		(5,713,598)	[5]
Diagnostics Segment [Member] | UNITED STATES
Tc99m tilmanocept sales revenue
Total assets, net of depreciation and amortization		3,815,271				4,161,029				3,815,271		4,161,029
Diagnostics Segment [Member] | Non-US [Member]
Tc99m tilmanocept sales revenue										39,601		19,075
Total assets, net of depreciation and amortization		131,752				410,666				131,752		410,666
Therapeutics Segment [Member]
Tc99m tilmanocept license revenue
Grant and other revenue										124,766
Revenues										124,766
Cost of goods sold, excluding depreciation and amortization
Research and Development Expense										762,151		730,895
Selling, general and administrative expenses, excluding depreciation and amortization	[1]									63,158		123,884
Depreciation, Depletion and Amortization, Nonproduction	[2]
Income (loss) from operations	[3]									(700,543)		(854,779)
Other income (expense), excluding equity in the loss of R-NAV, LLC	[4]
Equity in loss of R-NAV, LLC
Net loss from continuing operations										(700,543)		(854,779)
Loss from discontinued operations, net of tax effect													[5]
Net loss										(700,543)		(854,779)
Capital expenditures
Net loss from continuing operations										(700,543)		(854,779)
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax													[5]
Therapeutics Segment [Member] | UNITED STATES
Tc99m tilmanocept sales revenue
Total assets, net of depreciation and amortization		15,075								15,075
Therapeutics Segment [Member] | Non-US [Member]
Tc99m tilmanocept sales revenue
Total assets, net of depreciation and amortization
Corporate Segment [Member]
Tc99m tilmanocept license revenue
Grant and other revenue
Revenues
Cost of goods sold, excluding depreciation and amortization
Research and Development Expense
Selling, general and administrative expenses, excluding depreciation and amortization	[1]									7,403,329		10,242,066
Depreciation, Depletion and Amortization, Nonproduction	[2]									397,232		290,105
Income (loss) from operations	[3]									(7,800,561)		(10,532,171)
Other income (expense), excluding equity in the loss of R-NAV, LLC	[4]									2,786,007		(4,298,604)
Equity in loss of R-NAV, LLC										(15,159)		(305,253)
Net loss from continuing operations										(5,029,713)		(15,136,028)
Loss from discontinued operations, net of tax effect												1,194,660	[5]
Net loss										(5,029,713)		(13,941,368)
Capital expenditures										1,847		12,412
Net loss from continuing operations										(5,029,713)		(15,136,028)
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax												1,194,660	[5]
Corporate Segment [Member] | UNITED STATES
Tc99m tilmanocept sales revenue
Total assets, net of depreciation and amortization		8,498,797				10,391,805				8,498,797		10,391,805
Corporate Segment [Member] | Non-US [Member]
Tc99m tilmanocept sales revenue
Total assets, net of depreciation and amortization		$ 781				$ 1,013				$ 781		$ 1,013
[1]	General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments. Marketing and selling expenses are allocated to our individual reportable segments.
[2]	Depreciation and amortization is reflected in research and development ($0 and $10,617 for the years ended December 31, 2016 and 2015, respectively), and selling, general and administrative expenses ($397,232 and $460,839 for the years ended December 31, 2016 and 2015, respectively).
[3]	Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments.
[4]	Amounts consist primarily of interest income, interest expense, changes in fair value of financial instruments, and losses on debt extinguishment, which are not currently allocated to our individual reportable segments.
[5]	Amount not allocated to a reportable segment represents contingent consideration recognized related to 2015 GDS Business revenue royalties pursuant to the 2011 sale of the GDS Business to Devicor, net of tax effect. See Note 1(a).

Note 20 - Agreements (Details T

Note 20 - Agreements (Details Textual)

Mar. 03, 2017$ / sharesshares

Jul. 31, 2014USD ($)

Sep. 30, 2013USD ($)

Aug. 31, 2013

May 31, 2013

Jul. 31, 2012USD ($)shares

Dec. 31, 2011USD ($)

Nov. 30, 2009

Apr. 30, 2008USD ($)

Jan. 31, 2002USD ($)

Dec. 31, 2016USD ($)$ / shares

Dec. 31, 2015USD ($)$ / shares

Dec. 31, 2014USD ($)

Common Stock, Par or Stated Value Per Share | $ / shares

$ 0.001

$ 0.001

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

[1]

$ 0.33

Research and Development Expense

$ 7,138,080

$ 10,562,729

$ 15,116,978

Minimum [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 0.01

Maximum [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 3.04

Subsequent Event [Member]

Common Stock, Par or Stated Value Per Share | $ / shares

$ 0.001

Subsequent Event [Member] | Series NN Warrants [Member] | UCSD [Member]

Class of Warrant or Right, Term

5 years

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

1,000,000

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 1.50

Reliable Supply Agreement [Member]

Long-term Contract for Supplies, Initial Term

10 years

Long-term Contract for Supplies, Option to Extend, Term

3 years

Long-term Contract for Supplies, Resolution Term

60 days

Purchases Under Manufacture and Supply Agreement

$ 1,100,000

225,000

300,000

Purchase Orders Issued

525,000

Agreement Expiration Date

2019-11

Nordion Supply Agreement [Member]

Long-term Contract for Supplies, Initial Term

3 years

Purchases Under Clinical Supply Agreement

43,000

244,000

505,000

Agreement Expiration Date

2016-05

PETNET Supply Agreement [Member]

Long-term Contract for Supplies, Initial Term

3 years

Purchases Under Manufacturing Agreement

826,000

855,000

2,200,000

Agreement Expiration Date

2016-08

OsoBio Supply Agreement [Member]

Long-term Contract for Supplies, Resolution Term

60 days

Purchase Orders Issued

$ 562,000

Purchases Under Manufacturing Agreement

1,200,000

472,000

96,000

Gipharma Supply Agreement [Member]

Long-term Contract for Supplies, Initial Term

3 years

Long-term Contract for Supplies, Resolution Term

30 years

Purchase Orders Issued

1,500

Long-term Contract for Supplies, Renewal Term

1 year

Long-term Contract for Supplies, Notice Period Prior to Automatic Renewal

180 days

Long-term Contract for Supplies, Notice Period

60 days

Purchases Under Service and Supply Master Agreement

149,000

677,000

272,000

Tc99m Tilmanocept License Agreement [Member]

License Issue Fee

$ 25,000

License Maintenance Fee

25,000

Minimum Annual Royalty

$ 25,000

Tc99m Tilmanocept License Agreement [Member] | Outside the Territory [Member] | Cost of Sales [Member]

License Costs

2,000

1,000

1,000

Expanded Tc99m Tilmanocept License Agreement [Member]

License Issue Fee

$ 25,000

License Maintenance Fee

25,000

Minimum Annual Royalty

$ 25,000

Research and Development Expense

$ 25,000

Tilmanocept License Agreement [Member]

License Issue Fee

25,000

License Maintenance Fee

25,000

Minimum Annual Royalty

$ 25,000

Research and Development Expense

199,000

152,000

25,000

Astra Zeneca Agreement [Member]

License Costs

$ 5,000,000

Research and Development Expense

$ 116,000

80,000

81,000

Milestone Payments, Maximum, Cash, Clinical Development and Regulatory Filing Milestones

6,500,000

Milestone Payments, Maximum, Cash, Due Following Receipt of Regulatory Approvals and Initiation of Commercial Sales

$ 11,000,000

Alseres Pharmaceuticals Agreement [Member]

Research and Development Expense

$ 5,000

$ 42,000

Sublicense Execution Payment, Cash Paid

$ 175,000

Stock Issued During Period, Shares Issued for Sublicense Fee | shares

300,000

Milestone Payments, Maximum, Cash

$ 2,900,000

Milestone Payments, Maximum, Cash, At the Time of Product Registration or Upon Commercial Sales

$ 2,500,000

Stock Issued During Period, Shares Issued or Issuable for Sublicense Fee | shares

1,150,000

Stock Issued During Period, Shares Issued or Issuable for Sublicense Fee, At the Time of Product Registration or Upon Commercial Sales | shares

950,000

Employment Agreement [Member] | Minimum [Member]

Ratio of Entitled Salary

1.3

Employment Agreement [Member] | Maximum [Member]

Ratio of Entitled Salary

2.75

Loss Contingency, Estimate of Possible Loss

$ 1,900,000

[1]

Weighted average exercise price.

Note 21 - Leases (Details Textu

Note 21 - Leases (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Operating Leases, Rent Expense, Net	$ 187,000	$ 217,000	$ 357,000

Note 21 - Leases - Summary of F

Note 21 - Leases - Summary of Future Minimum Lease Payments (Details)	Dec. 31, 2016USD ($)
2,017	$ 277,946
2,018	284,246
2,019	290,734
2,020	297,405
2,021	304,201
Thereafter	253,339
Total	$ 1,707,871

Note 22 - Employee Benefit Pl85

Note 22 - Employee Benefit Plan (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Defined Contribution Plan, Cost	$ 47,000	$ 73,000	$ 83,000

Note 23 - Supplemental Disclo86

Note 23 - Supplemental Disclosure for Statements of Cash Flows (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Jul. 15, 2014	Mar. 31, 2014
Interest Paid, Net		$ 5,500,000	$ 4,600,000	$ 2,900,000
Stock Issued During Period, Shares, Employee Benefit Plan		67,002	68,157	36,455
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution		$ 120,800	$ 117,099	$ 100,043
Prepaid Insurance		348,000
Notes Payable End of Term Fees			1,000,000	2,400,000
Derivative Liability	$ 63,000	63,000	63,000
Preferred Stock Dividends and Other Adjustments			46,000
R-NAV [Member]
Equity Method Investment, Promissory Note Payable				666,666	$ 666,666
Macrophage Therapeutics [Member] | Convertible Preferred Stock [Member]
Preferred Stock Dividends and Other Adjustments	$ 46,000		$ 46,000
Capital Royalty Group, Term Loan [Member]
Payments to Collection of Collateral on Claims of Default		778,000
Payments to Prepayment Premium on Claims of Default		$ 2,100,000
Note Payable to IPFS [Member]
Debt Instrument, Interest Rate, Stated Percentage		8.99%
Oxford Finance, LLC [Member]
Debt Instrument, Interest Rate, Stated Percentage						8.50%
Warrants and Rights Outstanding				$ 465,000

Note 24 - Selected Quarterly 87

Note 24 - Selected Quarterly Financial Data (Unaudited) - Quarterly Financial Information (Details) - USD ($)	3 Months Ended																12 Months Ended
	Dec. 31, 2016		Sep. 30, 2016		Jun. 30, 2016		Mar. 31, 2016		Dec. 31, 2015		Sep. 30, 2015		Jun. 30, 2015		Mar. 31, 2015		Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
Tc99m tilmanocept sales revenue	$ 9,000		$ 18,000		$ 4,000		$ 9,000		$ 6,000		$ 9,000				$ 4,000		$ 39,601		$ 19,075		$ 13,200
Tc99m tilmanocept license revenue			1,296,000		246,000		254,000		250,000		550,000		250,000		83,000		1,795,625		1,133,333		300,000
Grant and other revenue	1,022,000		511,000		917,000		686,000		540,000		477,000		654,000		190,000		3,136,408		1,860,953		1,740,896
Gross profit	975,000		1,821,000		1,166,000		947,000		796,000		1,034,000		904,000		276,000		4,909,374		3,010,135		2,051,470
Operating expenses	4,215,000		2,731,000		3,407,000		4,705,000		4,256,000		5,947,000		4,348,000		6,900,000		15,058,116		21,450,875		24,642,962
Loss from operations	(3,240,000)		(910,000)		(2,241,000)		(3,758,000)		(3,463,000)		(4,912,000)		(3,443,000)		(6,623,000)		(10,148,742)	[1]	(18,440,740)	[1]	(22,591,492)
Loss from continuing operations	(2,118,000)		(1,761,000)		(817,000)		(2,682,000)		(1,946,000)		(6,509,000)		(8,171,000)		(5,983,000)
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax	(1,764,000)		1,702,000		(5,865,000)		(1,004,000)		(564,000)		(1,562,000)		(1,520,000)		(1,309,000)		(6,931,137)		(4,518,938)	[2]	(5,367,801)
Net loss attributable to common stockholders	$ (3,882,000)		$ (59,000)		$ (6,681,000)		$ (3,686,000)		$ (2,510,000)		$ (8,071,000)		$ (9,691,000)		$ (7,337,000)		$ (14,308,383)		$ (27,608,680)		$ (35,726,669)
Loss per common share (basic and diluted):
Continuing operations (in dollars per share)	$ (0.01)	[3]	$ (0.01)	[3]	$ 0	[3]	$ (0.02)	[3]	$ (0.02)	[3]	$ (0.04)	[3]	$ (0.05)	[3]	$ (0.04)	[3]	$ (0.05)		$ (0.15)		$ (0.20)
Discontinued operations (in dollars per share)	(0.01)	[3]	0.01	[3]	(0.04)	[3]	0	[3]	0	[3]	(0.01)	[3]	(0.01)	[3]	(0.01)	[3]	(0.04)		(0.03)		(0.04)
Attributable to common stockholders (in dollars per share)	$ (0.02)	[3]	$ 0	[3]	$ (0.04)	[3]	$ (0.02)	[3]	$ (0.02)	[3]	$ (0.05)	[3]	$ (0.06)	[3]	$ (0.05)	[3]	$ (0.09)		$ (0.18)		$ (0.24)
Tc99m tilmanocept sales revenue	$ 9,000		$ 18,000		$ 4,000		$ 9,000		$ 6,000		$ 9,000				$ 4,000		$ 39,601		$ 19,075		$ 13,200
Tc99m tilmanocept license revenue			1,296,000		246,000		254,000		250,000		550,000		250,000		83,000		1,795,625		1,133,333		300,000
Grant and other revenue	1,022,000		511,000		917,000		686,000		540,000		477,000		654,000		190,000		3,136,408		1,860,953		1,740,896
Gross profit	975,000		1,821,000		1,166,000		947,000		796,000		1,034,000		904,000		276,000		4,909,374		3,010,135		2,051,470
Operating expenses	4,215,000		2,731,000		3,407,000		4,705,000		4,256,000		5,947,000		4,348,000		6,900,000		15,058,116		21,450,875		24,642,962
Loss from operations	(3,240,000)		(910,000)		(2,241,000)		(3,758,000)		(3,463,000)		(4,912,000)		(3,443,000)		(6,623,000)		(10,148,742)	[1]	(18,440,740)	[1]	(22,591,492)
Loss from continuing operations	(2,118,000)		(1,761,000)		(817,000)		(2,682,000)		(1,946,000)		(6,509,000)		(8,171,000)		(5,983,000)
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax	(1,764,000)		1,702,000		(5,865,000)		(1,004,000)		(564,000)		(1,562,000)		(1,520,000)		(1,309,000)		(6,931,137)		(4,518,938)	[2]	(5,367,801)
Net loss attributable to common stockholders	$ (3,882,000)		$ (59,000)		$ (6,681,000)		$ (3,686,000)		$ (2,510,000)		$ (8,071,000)		$ (9,691,000)		$ (7,337,000)		$ (14,308,383)		$ (27,608,680)		$ (35,726,669)
[1]	Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments.
[2]	Amount not allocated to a reportable segment represents contingent consideration recognized related to 2015 GDS Business revenue royalties pursuant to the 2011 sale of the GDS Business to Devicor, net of tax effect. See Note 1(a).
[3]	Net loss per share is computed independently for each of the quarters presented. Therefore the sum of the quarterly per-share calculations will not necessarily equal the annual per share calculation.

Note 25 - Subsequent Events (De

Note 25 - Subsequent Events (Details Textual) - USD ($)		Mar. 03, 2017	Jan. 17, 2017	Jan. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Common Stock, Par or Stated Value Per Share					$ 0.001	$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights	[1]				$ 0.33
Cash					$ 1,539,325	$ 7,166,260	$ 5,479,006	$ 32,939,026
CRG Loan Agreement, Ohio Case [Member]
Release of Cash Held in Escrow		$ 2,000,000
CRG Loan Agreement, Texas Case [Member]
Release of Cash Held in Escrow		3,000,000
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.01
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 3.04
Term Loan Agreement [Member] | Cardinal Health 414 [Member]
Letters of Credit Outstanding, Amount		7,000,000
Term Loan Agreement [Member] | CRG [Member]
Letters of Credit Outstanding, Amount		12,000,000
CRG [Member] | Term Loan Agreement [Member]
Debt Instrument, Final Payoff Amount, Threshold Above Which the Reporting Entity Will First Pay Without Resorting to Letter of Credit		59,000,000
CRG [Member] | Term Loan Agreement [Member] | Maximum [Member]
Debt Instrument, Agreed-upon Final Payoff Amount		66,000,000
PPCO [Member] | Platinum Loan Agreement [Member]
Repayments of Debt		7,700,000
Convertible Debt		$ 1,900,000
Subsequent Event [Member]
Common Stock, Par or Stated Value Per Share		$ 0.001
Cash		$ 15,600,000
Payables		3,700,000
Subsequent Event [Member] | Chief Executive Officer [Member]
Class of Warrant or Right, Exercises in Period			5,411,850
Proceeds from Warrant Exercises			$ 54,119
Subsequent Event [Member] | CRG Loan Agreement, Ohio Case [Member]
Release of Cash Held in Escrow		2,000,000
Subsequent Event [Member] | CRG Loan Agreement, Texas Case [Member]
Release of Cash Held in Escrow		3,000,000
Subsequent Event [Member] | Term Loan Agreement [Member] | Cardinal Health 414 [Member]
Letters of Credit Outstanding, Amount		7,000,000
Subsequent Event [Member] | Term Loan Agreement [Member] | CRG [Member]
Letters of Credit Outstanding, Amount		12,000,000
Debt Instrument, Final Payoff Amount, Threshold Above Which the Reporting Entity Will First Pay Without Resorting to Letter of Credit		59,000,000
Subsequent Event [Member] | CRG [Member]
Asserted Payoff Amount				$ 63,198,774.46
Subsequent Event [Member] | CRG [Member] | Term Loan Agreement [Member]
Repayments of Debt		59,000,000
Debt Instrument, Final Payoff Amount, Threshold Above Which the Reporting Entity Will First Pay Without Resorting to Letter of Credit		59,000,000
Subsequent Event [Member] | CRG [Member] | Term Loan Agreement [Member] | Minimum [Member]
Debt Instrument, Agreed-upon Final Payoff Amount		47,000,000
Subsequent Event [Member] | CRG [Member] | Term Loan Agreement [Member] | Maximum [Member]
Debt Instrument, Agreed-upon Final Payoff Amount		66,000,000
Subsequent Event [Member] | PPCO [Member] | Platinum Loan Agreement [Member]
Repayments of Debt		7,700,000
Convertible Debt		$ 1,900,000
Subsequent Event [Member] | Series NN Warrants [Member] | UCSD [Member]
Class of Warrant or Right, Term		5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1.50
Subsequent Event [Member] | Series NN Warrants [Member] | Cardinal Health 414 [Member]
Class of Warrant or Right, Term		5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		10,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1.50
Sale of Assets to Cardinal Health 414 [Member] | Subsequent Event [Member]
Sale of Assets, Cash Received from Buyer, After Adjustments, Inventory Transferred		$ 80,600,000
Sale of Assets, Cash Received from Buyer, After Adjustments, Advances of Guaranteed Earnout Payments		3,000,000
Purchase Agreement, Maximum Earnout Payments		$ 230,000,000
Purchase Agreement, Earnout Payments, Term		10 years
Purchase Agreement, Earnout Payments, Guaranteed		$ 20,100,000
Proceeds from Estimated Accrued Revenue Sharing Payments		$ 1,200,000
[1]	Weighted average exercise price.